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Abstract 
 
Peptidoglycan glycosyltransferases (PGTs) are highly conserved bacterial enzymes 
that catalyze the polymerization of the lipidic disaccharide, Lipid II, to form individual 
peptidoglycan (PG) strands which are subsequently cross-linked to form mature PG, the 
major skeletal component of the bacterial cell wall. Recent advances in the preparation of 
well-defined PGT substrates have enabled the biochemical characterization of Lipid II 
polymerization by the PGTs. In the course of these studies, we have observed that a 
distinctive lag phase in the initial rate of PG synthesis by the PGTs can be abrogated if the 
enzyme is preincubated with Lipid IV, the shortest PG fragment.  
The origins of this lag phase are intriguing because the chemical transformation 
involved in coupling Lipid II to yield Lipid IV is identical to the transformation involved in 
the synthesis of longer PG fragments from Lipid II. Crystallographic structures of the PGTs 
with Moenomycin A, an inhibitor that is believed to bind to the same site as Lipid IV, 
suggest that the PGTs possess flexible regions near the putative active site that can undergo 
substrate-induced conformational changes to accelerate PG synthesis. However, there is 
currently no structural evidence on how the PGTs interact with its substrates.  
The work in this thesis lays the foundation for pursuing a solution structure of a Lipid 
IV bound PGT complex by Nuclear Magnetic Resonance (NMR) spectroscopy, enabling the 
study of important enzyme conformational states and structural dynamics involved in PG 
iv 
 
synthesis. Specifically, Chapter 2 of this thesis presents the biochemical evidence that the 
preincubation of the PGTs with a Lipid IV derivative, Gal-Lipid IV abrogates the lag phase 
and accelerates the initial rate of PG synthesis. Chapter 3 presents a robust methodology for 
obtaining multimilligram quantities of isotope labeled, monodisperse and monomeric SgtB, a 
PGT from a clinically relevant pathogen, Staphylococcus aureus for solution structural 
studies. Chapter 4 describes the systematic development of a methodology for producing a 
well-behaved, stable sample of Moenomycin A bound SgtB for NMR spectroscopy. Chapter 
5 delineates the adaptation of the methodology described in Chapter 4 for pursuing the 
solution structure of Lipid IV bound SgtB. 
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Chapter One: Introduction to the Biosynthesis of Peptidoglycan 
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1.1 Overview on the biosynthesis of peptidoglycan 
Peptidoglycan (PG) is the major skeletal component of the bacterial cell wall that is 
essential for the survival of bacteria under environmental conditions which induce high 
internal osmotic pressure.1,2 It is a unique and highly conserved organelle among most 
bacteria and its biosynthetic pathway has been targeted by some of the world’s most 
successful antibiotics, namely Penicillin G and Vancomycin.3,4,5 PG derives its strength and 
rigidity from the formation of a complex web of glycan chain polymers that are linked 
together by their peptide side chains.6,7 Presumably, this enables the PG to function as an 
exo-skeleton that ensures the integrity of the fluid cytoplasmic membrane, preventing lysis.8 
Structurally, these glycan chain polymers are composed of repeating disaccharide units 
of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) residues. Short 
peptides attached as appendages on the lactic acid moiety of the N-acetylmuramic acid 
enable adjacent glycan strands to be cross-linked through an amide bond.9   
The biosynthesis of PG can be delineated into three distinct stages (Figure 1.1).10,11,12 
Briefly, the first stage involves the conversion of UDP-GlcNAc into UDP-MurNAc-
pentapeptide through a series of enzymatic transformations performed in the cytoplasm.13 In 
the second stage of the biosynthesis, the UDP-MurNAc-pentapeptide is brought to the inner 
face of the cytoplasmic membrane by the attachment of a C55-Lipid, undecaprenyl 
pyrophosphate by MraY to generate Lipid I.14 MurG then glycosylates Lipid I with GlcNAc 
to form a β(1,4)-linked disaccharide  
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Figure 1.1 Biosynthesis of Peptidoglycan 
 
called Lipid II.15,16,17 Lipid II is then brought to the outer leaflet of the cytoplasmic 
membrane by a putative flippase for the final stage of PG synthesis.18,19,20 The final assembly 
of peptidoglycan from Lipid II is performed by two classes of enzymes: the peptidoglycan 
glycosyltransferases (PGT) and the transpeptidases (TP).21 PGTs and TPs can exist as 
independent, monofunctional proteins or alternately, as separate domains that are combined 
into a single bifunctional protein (e.g. Staphylococcus aureus Penicillin-binding Protein 2) 
(Figure 1.2). 
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Figure 1.2 Topology of the PGTs. PGT enzyme can exist either as (a) a monofunctional 
protein that is anchored to the cytoplasmic membrane via a transmembrane helix, or (b) as a 
distinct domain within a bifunctional enzyme. 
 
 PGTs initiate the process by joining two identical units of Lipid II via a β(1,4) 
glycosidic bond between the C4-hydroxyl group of GlcNAc from the acceptor and the C1-
anomeric end of MurNAc from the donor to give a tetrasaccharide product, Lipid IV. The 
undecaprenyl pyrophosphate lipid moiety from the donor is released, presumably providing 
the driving force for the reaction. Lipid IV is elongated by the addition of another Lipid II 
unit. This process is repeated multiple times to form nascent glycan strands bearing the 
desired polymer length properties. Finally, these nascent glycan strands are cross-linked 
together via their peptide appendages by the TPs to yield peptidoglycan. 
 
1.2 Progress towards understanding the mechanistic details of the PGTs 
The polymerase activity of the PGT is a key component of the cell wall biosynthetic 
machinery, yet the mechanistic details underlying the transglycosylation reaction performed 
by the PGTs have only recently emerged. Historically, the lack of pure Lipid II substrate as 
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well as chemically defined substrate fragments of PG presented a major impediment to PGT 
research.22 
In 2001, the development of a chemoenzymatic synthesis of the Lipid II substrate opened 
the door to the efficient preparation of radio-labeled Lipid II substrates. This circumvented 
the crude and low yielding preparation of radiolabeled Lipid II from bacterial membrane 
extracts.23,24,25  As a result, PG synthesis from Lipid II could be monitored in a quantitative 
fashion by radiological assays that in turn enabled the preliminary characterization of PGT 
reaction kinetics (Figure 1.3).26,27 Synthetic access to Lipid IV provided a roadmap for 
preparing various PG fragments that were crucial for probing the enzymatic process of 
synthesizing PG.28 For instance, the ability to prepare Gal-Lipid IV, a PG fragment that 
cannot be glycosylated in a β(1,4) fashion on the nonreducing end showed that the nascent 
glycan strand is elongated on the reducing end.29,30 The ability to prepare PG fragments with 
varying lipid lengths revealed that the donor binding site of the PGT requires a substrate 
bearing a lipid chain longer than 20 carbon atoms for polymerization.31 This suggests that the 
lipidic moiety of the donor substrate forms an important interaction with the enzyme that is 
required for transglycosylation. 
The availability of well-defined substrates also spurred the development new 
chromatographic means of analyzing the PG polymer products of the reaction. Specifically, 
the development of a high-resolution SDS-PAGE chromatographic assay that separates 
glycan polymers based on length revealed that the PGTs function as processive polymerases: 
the resultant nascent PG is not released into  
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Figure 1.3 Biochemical tools for studying the PGTs. (a) 14C-radiolabeled Lipid II can be 
prepared by using MurG to glycosylate Lipid I with UDP-[14C]GlcNAc. Lipid I is chemically 
synthesized. (b) Paper chromatography can be used to separate PG from unreacted Lipid II 
substrate. This format is often used for analyzing PGT kinetics by monitoring the rates of 
substrate conversion to PG over time. SDS-PAGE gel chromatography of PG fragments was 
developed to analyze the distribution of PG fragment size.  
 
bulk solution after each transglycosylation but rather, is utilized as the donor for a subsequent 
round of transglycosylation.32 
Taken together, these results enabled a working model of PGT polymerization to be 
proposed. Briefly, the process is initiated by the uptake of two molecules of Lipid II by the 
PGTs to synthesize a nascent PG fragment, Lipid IV. In order for the PGT to elongate Lipid 
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IV on its reducing end in a processive manner, the same Lipid IV molecule has to be 
translocated to the donor binding site so that another Lipid II molecule can bind as an 
acceptor (Figure 1.4). By performing multiple cycles of transglycosylation and translocation, 
the nascent PG is elongated to yield a glycan polymer of desired length before it is released. 
 
Figure 1.4 Transglycosylation and translocation of substrates by PGTs. The donor site and 
acceptor site both bind a Lipid II molecule. The PGT transglycosylates the Lipid II substrates 
to yield Lipid IV. Lipid IV is then translocated to the donor site so that the acceptor site can 
take up Lipid II to perform another transglycosylation. Figure adapted from Wang, T.S., 
Lupoli, T.J., Sumida Y., Tsukamoto H., Wu, Y., Rebets, Y., Kahne, D.E., Walker, S. (2011) 
J. Am. Chem. Soc. 133, 8528-8530. 
 
Apparent from this model and the biochemical evidence thus far, PG synthesis is a 
complex operation for the PGT enzyme. A molecular picture of how the PGTs physically 
interact with its substrates, manage this process of shuffling substrates between binding sites, 
and perform transglycosylations would greatly enhance our understanding of PG synthesis. 
Structural studies of the PGTs have been hampered by the challenges of producing and 
handling these membrane-associated proteins, which aggregate rapidly. Early attempts to 
overexpress PGTs that did not possess an aggregation prone segment of the protein – a 
transmembrane α-helical anchor - resulted in protein that had low enzymatic activity or 
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degraded rapidly.33,34,35,36 Fortunately, constructs that produced stable protein that can be 
purified to homogeneity were eventually identified, leading to four PGT X-ray crystal 
structures derived from Staphylococcus aureus PBP2, Aquifex aeolicus PBP1A, Escherichia 
coli PBP1B and Staphylococcus aureus SgtB.37,38,39,40 These studies revealed that the PGTs 
are highly α-helical proteins that comprise of two lobes whose boundaries are demarcated by 
an extensive cleft. Remarkably, the structures bear a strong resemblance to a well-
characterized PG hydrolase, the bacteriophage λ-lysozyme that catalyzes the cleavage of the 
β(1,4)-glycosidic bond between MurNAc and GlcNAc – the reverse reaction of PG 
synthesis.38,41 As a result, it is postulated that the residues within this cleft are responsible for 
binding the nascent PG and Lipid II and performing the transglycosylation reaction. 
Sequence alignments of the PGTs with λ-lysozyme along with mutagenesis studies on the 
PGTs suggest a conserved glutamic acid residue present within the cleft may function as a 
catalytic base that deprotonates the C4-hydroxyl of GlcNAc moiety of Lipid II to attack the 
C1 MurNAc from the nascent PG.42 Unfortunately, the molecular details of how the 
substrates interact with the PGTs remain unknown because these crystal structures did not 
incorporate any PG fragment or substrate. As a result, one cannot ascertain whether the 
observed PGT structural conformation is functionally relevant in PG synthesis.  
 The structures of Staphylococcus aureus PBP2 and Aquifex aeolicus PBP1A were 
solved in the presence and absence of Moenomycin A, the only known natural inhibitor of 
the PGTs, revealing changes in conformation in the lower lobe region between the apo-  
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Figure 1.5 Structure of PGTs from S. aureus PBP2 and A. aeolicus PBP1A. Lower lobe 
region is denoted in blue, blue arrows indicate segments with missing electron density. (a) 
apo S. aureus PBP2 PGT domain. (b) Moenomycin A bound S. aureus PBP2 PGT domain. 
(c) apo A. aeolicus PBP1A PGT domain. (d) C10-Neryl-Moenomycin A bound A. aeolicus 
PBP1A PGT domain.  C10-Neryl-Moenomycin A is a derivative of Moenomycin A that has a 
C10-Neryl lipid chain in place of a C25-moenocinol lipid chain.  
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enzyme and the Moenomycin A bound form.37,43 Moreover, poor electron density in loop 
segments that bridge the α-helices of the lower lobe also suggests that the lower lobe is 
floppy and some of these conformational dynamics may be important in performing its 
catalytic function (Figure 1.5).44,45,46 
 
1.3 Probing the conformational dynamics of the PGTs by NMR 
 PGT structures from X-ray crystallography have presented molecular detail into the 
structural form of the enzymes. However, the very nature of crystallographic technique often 
reveals only the “ground-state” conformation that may not be crucial for enzymatic function, 
leading to an incomplete structural interpretation of how a biochemical transformation 
physically occurs.47,48,49,50 In Chapter 2, we show that the PGT’s characteristic initial lag-
phase kinetics can be abrogated by precubating the enzyme with Gal-Lipid IV.51 This 
observation suggests that the association of Gal-Lipid IV with the PGT enable the enzyme to 
access a “rate-enhanced” state. There is no structural evidence that explains why the 
transglycosylation of two Lipid II molecules is slower than that between Gal-Lipid IV and 
Lipid II. We postulate that the PGTs can undergo a conformational change to accelerate the 
initiation of PG synthesis. To begin, a structure of a Gal-Lipid IV bound PGT will be 
required to compare and contrast the differences in conformation, as well as changes in 
structural mobility between the apo and substrate-bound enzyme.  
Nuclear Magnetic Resonance (NMR) Spectroscopy is the only structural technique 
that enables one to obtain a three-dimensional structure of a protein and quantitatively probe 
the conformational dynamics of the protein at an atomic-level without introducing additional 
structural perturbations.52,53 The time scale available to NMR techniques ranges over 15 
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orders of magnitude (10-12 to 103 s), covering all of the relevant dynamic motions in 
proteins.54 However, there are two major limitations in implementing this technique, both of 
which stem from the protein sample itself. First of all, the protein complex of interest 
(including the ligands and any associated detergent micelle) has to be small – under 35 kDa 
for the practical purposes of obtaining a solution structure.53 Secondly, one needs to be able 
to produce multi-milligram quantities of the protein in a form that incorporates NMR-active 
nuclei (e.g. 13C, 15N), is homogeneous and stable at a pH below 7.0, and most importantly,  
does not form aggregates over time upon extensive exposure to room temperature (on the 
order of weeks).55,56,57  
Staphylococcus aureus SgtB is a 26.2 kDa monomeric and monofunctional PGT that 
was successfully crystallized by Pfizer Research and Development in a form that was bound 
to Moenomycin A.40 Although the protein requirements for crystallographic studies are less 
demanding (the protein is not isotopically-labeled, does not require extended stability at 
room temperature), it nonetheless requires the ability to produce multi-milligram quantities 
of pure protein that is properly folded and monodisperse. The existence of an efficient 
preparation method as well as small mass make the SgtB construct utilized by Pfizer an ideal 
starting ground for the development of a PGT NMR sample aimed at elucidating the solution 
structure of Gal-Lipid IV bound PGT complex and its associated conformational dynamics. 
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1.4 Research Statement 
The polymerase activity of the PGTs is a key component of the cell wall biosynthetic 
machinery. Thus far, there are no structural data that can give us insight into how the 
complex polymerase activity of the PGTs is physically performed. The research in this thesis 
examines how the observation of a rate-enhancement effect on the PGTs by Gal-Lipid IV 
inspires the systematic development of an SgtB NMR sample that can potentially yield 
insights into the structural configuration of Gal-Lipid IV bound SgtB, enabling the use of 
NMR spectroscopic techniques for the study of PGT conformational dynamics.  
 Chapter 2 of this thesis details the observation of a rate-enhancement effect on the 
PGTs by Gal-Lipid IV. Chapter 3 describes the development of a high-yielding, rapid and 
robust preparation of S. aureus SgtB protein that is monomeric and monodisperse in a format 
suited for the production of an SgtB NMR sample. Chapter 4 details the development of a 
method for preparing a Moenomycin A bound SgtB protein sample that is stable at room 
temperature for more than three weeks that yields high quality [1H,15N]-HSQC spectra, 
indicating the feasibility for conducting solution structure studies on this sample. Because the 
modular format of this sample preparation method allows for the incorporation of various 
SgtB ligands, Chapter 5 outlines the path towards obtaining a Lipid IV bound SgtB solution 
structure. In closing, we show how the ability to generate multimilligram quantities of 
monomeric, monodisperse SgtB in a highly efficient and scalable manner enables the 
practical implementation of a high-throughput screen for new inhibitors of SgtB that may be 
the basis for new antibacterials. 
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Chapter Two: PGT Rate Enhancement by Peptidoglycan Fragment Analog  
Gal-Lipid IV 
 
 
Work in this chapter is adapted with permission from: 
Wang, T.S.; Lupoli, T. J., Sumida, Y., Tsukamoto, H., Wu, Y., Rebets, Y., Kahne, D.E., and 
Walker S. (2011) Primer preactivation of peptidoglycan polymerases, J. Am. Chem. Soc. 133, 
8528-8530. Copyright 2011 American Chemical Society.  
Individual contributions are laid out in Section 2.3 of this chapter. 
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2.1 Introduction 
Peptidoglycan glycosyltransferases (PGTs) are highly conserved bacterial enzymes 
that catalyze Lipid II polymerization to form peptidoglycan (PG) polymers that constitute the 
bulk of the bacterial cell wall.1 These PGT enzymes can exists either as independent, 
monofunctional proteins or alternately, as separate domains that are combined into a single 
bifunctional protein (e.g. Staphylococcus aureus Penicillin-binding Protein 2). Because the 
bacterial cell wall integrity has to be maintained during growth and cell division to prevent 
lysis, it has been proposed that the PGTs function within a tightly coordinated multi-protein 
complex that can speed up or shut down cell wall synthesis in concert with growth and 
division signals.2,3,4  
The emergence of antibacterial resistance in our current drug arsenal has been a major 
driving force for discovering new druggable enzymatic targets for developing new 
antibacterials.5 The PGTs have emerged as a promising therapeutic target because of their 
essential role in PG synthesis.6,7 In order to design multiple drugs that can disrupt the 
function of the PGTs in different ways, a detailed understanding of their mechanism of action 
is required.8 Well-defined substrates and inhibitors of the peptidoglycan biosynthetic process 
have enabled researchers to piece together a view of how peptidoglycan (PG) is synthesized 
(Figure 2.1). In particular, we now know that Lipid II is the only substrate that is required for 
the PGTs to synthesize glycan polymers and that the PGTs utilize a processive mechanism to 
produce long glycan polymers.9 It has also been shown recently that polymer extension 
proceeds via the reducing end of the glycan chain.10  
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Figure 2.1 Biosynthesis of peptidoglycan. 
 
In the course of these studies, researchers have observed that the reaction time 
courses of different PGTs exhibit a prolonged lag phase that could be due to a slow 
conformational rearrangement of the enzyme to an active form and/or a slow first coupling 
step.9,11,12 We reasoned that if the formation of Lipid IV, the product of the first coupling of 
two Lipid II molecules, is rate-limiting, then the addition of Lipid IV should prime the 
enzyme and accelerate the polymerization of Lipid II.  
In this chapter, we show that Gal-Lipid IV, a PG fragment that is able to act as a 
glycosylation donor to Lipid II, enhances the PGT’s initial rate of polymerization. 
Additionally, we demonstrate how the availability of monodisperse and monomeric SgtB - 
the only well-behaved PGT in the group studied - is pivotal in demonstrating that the lag-
phase phenomenon is an intrinsic feature of the enzyme. This result, along with previous 
observations of various PGT structures, suggest that a conformational change is induced by 
the binding of Gal-Lipid IV by the PGTs, resulting in an “activated” elongation-competent 
state.    
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2.2 Results and Discussion 
2.2.1. Pre-incubation of PGTs with Gal-Lipid IV increases the rate of PG synthesis from 
Lipid II  
In order to test the hypothesis that Lipid IV can accelerate the initial rate of PG 
synthesis, we needed a Lipid IV substrate that is incapable of reacting with itself but is 
reactive with Lipid II to form peptidoglycan. We cannot use the natural Lipid IV substrate 
because it can be utilized as a monomeric building block by the PGT to give 
peptidoglycan.13,14 Perlstein and coworkers developed a Gal-Lipid IV substrate that cannot be 
glycosylated on the non-reducing end of Lipid IV by blocking it with Galactose.10 This 
blocked substrate can be easily prepared by incubating Lipid IV with UDP-Galactose in the 
presence of GalT enzyme, a β1-4 galactosetransferase that transfers Galactose to C4-
hydroxyl of terminal N-acetylglucosamine (GlcNAc) residues on a wide variety of 
molecules.15,16,17,18 By capping off the non-reducing end of Lipid IV, Gal-Lipid IV is 
incapable of reacting with itself but can be extended by sequential addition of Lipid II on the 
non-reducing end to form peptidoglycan (Figure 2.2).  
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Figure 2.2 Synthesized substrates used in analyzing PGT reactions. Compound 1: Lipid II, 
featuring a C35-lipid tail that balances solubility and reactivity. Naturally occurring Lipid II 
possesses a C55-undecaprenyl lipid tail that confers poor solubility and cannot be used in in-
vitro assays. Compound 2: Gal-Lipid II featuring a C35-lipid tail. Compound 3: Lipid IV, 
featuring a C35-lipid tail. Compound 4: Gal-Lipid IV, featuring a C35-lipid tail. 
 
Since Gal-Lipid IV functions as a "donor-only" substrate that mimics the product of 
the first coupling step of the PGT, we tested its effect on the reaction rate of Escherichia coli 
PBP1A, which contains an N-terminal PGT domain and a C-terminal transpeptidase domain. 
We incubated the enzyme for 20 minutes with Gal-Lipid IV to prime/activate the enzyme. 
Radiolabeled Lipid II was then added. The reaction mixtures were incubated for varying 
periods of time and then analyzed by paper chromatography, which separates the long 
peptidoglycan product from the shorter oligomeric starting materials Lipid II and Gal-Lipid 
IV. As a control, we prepared a separate reaction where we incubated the enzyme with a 
buffer aliquot that did not contain Gal-Lipid IV for 20 minutes before the addition of Lipid 
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II. Unlike the control reaction, there was no lag phase in the presence of Gal-Lipid IV, and 
the reaction rate was approximately 4-fold higher (Figure 2.3). 
 
Figure 2.3. Peptidoglycan synthesis by the PGT from E. coli PBP1A under the priming 
influence of various substrates. Blue: No priming substrate is added. Green: Gal-Lipid IV 
(compound 4) primed E. coli PBP1A. Red: Gal-Lipid II (compound 2) primed E. coli 
PBP1A.  
 
We repeated this series of experiments with another PGT, Escherichia coli PBP1B, 
and observed that Gal-Lipid IV had a similar rate-enhancement effect on the enzyme (Figure 
2.4a). Because the E. coli PBP1A and PBP1B are bifunctional enzymes with a distinct 
transpeptidase domain that is in close proximity to the PGT domain, we were curious as to 
whether the transpeptidase domain was involved with this rate-enhancement effect. TP-
truncated variants of the E. coli PBP1A and PBP1B displayed a characteristic lag-phase in 
the time course of peptidoglycan synthesis that is abrogated by the addition of Gal-Lipid IV, 
resulting in 5- and 2-fold rate enhancement respectively (Figure 2.4b and 2.4c). This allows 
us to conclude that this activation phenomenon is localized to the PGT domain of the 
enzyme. Because the PGTs tested thus far originated from Gram-negative bacteria, we 
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repeated the same set of experiments with the Staphylococcus aureus PBP2 and observed a 
2-fold rate enhancement (Figure 2.4d). This suggests that this activation phenomenon by 
Gal-Lipid IV may be general for the PGTs, although the magnitude of the rate enhancement 
varied depending on the enzyme. 
 
Figure 2.4 Summary of rate-enhancement effect by Gal-Lipid IV on various PGTs. (a) E. 
coli PBP1B primed by Gal-Lipid IV (green) vs. unprimed (purple). (b) E. coli PBP1B ∆TM 
primed by Gal-Lipid IV (green) vs. unprimed (purple). (c) E. coli PBP1B ∆TM primed by 
Gal-Lipid IV (green) vs. unprimed (purple). (d) S. aureus PBP2 primed by Gal-Lipid IV 
(green) vs. unprimed (purple). 
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2.2.2. The product distribution of Gal-Lipid IV activated PGTs suggests that Lipid IV 
increases the concentration of “elongation-competent” PGTs 
The Kahne and Walker labs have previously reported that PGTs produce long glycan 
polymers even at a 1:1 enzyme: substrate ratio.19 This remarkable insensitivity of PGT 
product lengths to the enzyme:substrate ratio can be explained if initiation is so much slower 
than elongation that only a small fraction of the available enzyme makes polymer before the 
substrate runs out.20,21,22 If Gal-Lipid IV does indeed increase the fraction of rate-enhanced 
“activated” enzyme, then its addition would be expected to decrease the glycan chain lengths 
produced at a given enzyme:substrate ratio, since more enzyme molecules would be 
competing for substrate.23,24 To test this prediction, we incubated Escherichia coli PBP1A in 
the presence or absence of Gal-Lipid IV and then added 7-fold excess of Lipid II. The 
product distribution was evaluated using an SDS-PAGE gel chromatographic method that 
separates products with single-disaccharide resolution.9 Consistent with this prediction, the 
addition of Gal-Lipid IV resulted in a decrease in product length. This suggests that Gal-
Lipid IV preincubation generates a higher concentration of “activated” PGT enzymes 
(Figure 2.5).  
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Figure 2.5 SDS-PAGE of PG polymers produced by E. coli PBP1A. Lanes (1–4): Control, 
no Gal-Lipid IV primer is added, resulting in longer peptidoglycan polymers. Lanes (5-8):  
Preincubation of Gal-Lipid IV, resulting in shorter peptidoglycan polymers, and notably 
faster consumption of substrate Lipid II. 
 
2.2.3 Initial rate-enhancement by Gal-Lipid IV does not depend on the aggregation 
state of the PGTs. 
Our experiments thus far have utilized preparations of PGTs that are soluble 
monodisperse aggregates. It is unclear whether these aggregates are a native state of the 
PGTs. It is possible that the observed lag phase may be an artifact of the enzyme having to 
function in a suboptimal, nonnative aggregated state.25,26 Nonnative protein aggregates are 
poorly folded and may not be able to efficiently access important conformational states that 
are required for enzymatic function. It is possible that the binding of Gal-Lipid IV may assist 
poorly folded PGT aggregates to access the "activated" state. 
SgtB is the only PGT that we were able to prepare in a pure, monodisperse and 
monomeric form (Figure 2.6).27 By incubating SgtB in the presence and absence of Gal-
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Lipid IV, we were able to observe 7-fold rate enhancement (Figure 2.7). We were able to 
infer that the ability to undergo rate acceleration by Gal-Lipid IV is not an artifact of the 
aggregation state of the PGTs. 
 
Figure 2.6 Isolating monomeric and monodisperse SgtB. (a) Size-exclusion profile of Ni-
NTA purified SgtB. The monomeric fraction M is isolated for enzymological studies. (b) 
SDS-PAGE gel of fraction M. (c) Rate-enhancement effect by Gal-Lipid IV on SgtB. 
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2.2.4. The synthesis of Lipid IV is rate-limiting in PG synthesis 
Our observation that the preincubation of PGTs with Gal-Lipid IV accelerates the 
initial rate of PG synthesis suggests that the formation of Lipid IV may be rate-limiting. In 
order to test this hypothesis, we prepared Gal-Lipid II, whose non-reducing end is blocked in 
the same manner as in Gal-Lipid IV. Gal-Lipid II was preincubated with E. coli PBP1A prior 
to initiating the reaction with Lipid II, but its presence did not accelerate the reaction. 
Because Gal-Lipid II, like Gal-Lipid IV, was incorporated into the newly synthesized PG, it 
can bind to the donor site of the PGT like Gal-Lipid IV but yet cannot influence it in the 
same manner (Figure 2.3). This experiment showed that initial rate-acceleration does not 
depend simply on having a functional "donor-only" substrate. Instead, the donor substrate 
must contain a tetrasaccharide or longer fragment of the elongating chain. Taken together, 
this data suggest that the slow step of PG synthesis involves the formation of Lipid IV.  
Thus far, we do not have any insight as to why the formation of Lipid IV is rate-
limiting on a molecular level. This is especially intriguing since the chemical transformation 
involved in coupling Lipid II to yield Lipid IV is identical in the elongation of higher PG 
fragments using Lipid II. A multitude of possibilities exist: Lipid IV may induce a 
conformational change in PGT such that (1) transglycosylation is more efficient, (2) the 
uptake of Lipid II substrate in the acceptor site is more efficient, or, Lipid IV simply binds 
more efficiently to the donor site than Lipid II (Figure 2.7). Previous studies by Dr. Andrew 
Wang from the Kahne lab estimated the affinity of Gal-Lipid IV towards PGT to be 7 fold of 
Lipid II.28  
Recent biochemical evidence support the notion that conformational changes in the 
enzyme bring about rate-enhancement:  E. coli PBP1B can undergo a similar rate 
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enhancement effect in the presence of an accessory protein, LpoB. This result shows that 
stronger affinity of Gal-Lipid IV for the PGT does not fully explain the observed rate-
enhancement, instead, the PGTs might possess a distinct "activated” conformation that can 
be similarly achieved through the binding of Lipid IV.29  
 
Figure 2.7 Possible causes of the observed initial lag phase kinetics in PGTs. (a) A 
conformational change into an “on/activated” form that makes transglycosylation is more 
efficient. (b) A conformational change into an “on/activated” form that makes uptake of 
Lipid II more efficient. (c) Binding of Lipid IV or interaction with LpoB may induce 
conformational changes to access the “on/activated” form.     
32 
 
Studies by Dr. Andrew Wang suggest that in the case of an E. coli PBP1A, Gal-Lipid 
IV may bind to the PGT in a similar fashion as Moenomycin A because preincubating the 
PGT with Gal-Lipid IV increases the IC50 of Moenomycin A by 5-fold over that of the 
untreated enzyme.30 This raises the question of whether the Moenomycin A bound PGT 
structure in any way reflects the Gal-Lipid IV bound/”activated” state of the PGT. Moreover, 
there may be other points of flexibility that are not revealed in the crystallized form of the 
protein that are essential for its catalytic function.  
This view portends the perceived conformational flexibility of the protein and how it 
may be crucial for its function in a physiological context. Previous structural work on the 
PGTs has revealed points of flexibility that are proximal to the putative active site of the 
enzyme. The lack of electron density on a series of PGT structures in the lower lobe region of 
the enzyme suggests that this region of the protein is highly disordered (Figure 
2.8).31,32,33,34,35 We need more information on the conformational changes that take place as 
the PGT interacts with its ligands. This sets up our motivation for pursuing the solution 
structure and studying the conformational dynamics of the PGTs using SgtB as a model 
system in Chapters 3 and 4. 
 
 
33 
 
 
Figure 2.8 Structure of PGTs from S. aureus PBP2 and A. aeolicus PBP1A. Lower lobe 
region is denoted in blue, blue arrows indicate segments with missing electron density. (a) 
apo S. aureus PBP2 PGT domain. (b) Moenomycin A bound S. aureus PBP2 PGT domain. 
(c) apo A. aeolicus PBP1A PGT domain. (d) C10-Neryl-Moenomycin A bound A. aeolicus 
PBP1A PGT domain.  C10-Neryl-Moenomycin A is a derivative of Moenomycin A that has a 
C10-Neryl lipid chain in place of a C25-moenocinol lipid chain.  
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2.3 Selected Materials and Methods 
2.3.1 Materials 
C35-Lipid II was synthesized and radiolabeled by Dr. Yuto Sumida as described previously.36 
C35-Lipid IV was synthesized and radiolabeled by Dr. Yi Zhang as previously reported.13 
Gal-Lipid II and Gal-Lipid IV were converted from C35-Lipid II and C35-Lipid IV, 
respectively, by Dr. Andrew Wang as described previously.10 Full-length E. coli PBP1A was 
purified by Dr. Andrew Wang and S. aureus PBP2 was purified by Dr. Yuriy Rebets 
following procedures described previously.9,19 TP truncated E. coli PBP1A(M1-N251) was 
purified by Dr. Andrew Wang as previously reported.19 Full length E. coli PBP1B plasmid 
was obtained from the Bernhardt lab (Harvard Medical School) and purified by Dr. Tania 
Lupoli as described. TP truncated mutant PBP1B (M1-S409) was cloned and purified by Dr. 
Tania Lupoli. S. aureus SgtB (D68-R269), overexpression plasmid was obtained from Dr. 
Alita Miller (Pfizer Global Research and Development, MTA:A12545) and purified by Yihui 
Wu as described in detail in Chapter 3 of this thesis. Moenomycin A was isolated from 
Flavomycin-80 feedstock (provided by Merck Research Laboratories) by Dr. Hirokazu 
Tsukamoto and Yihui Wu as previously described.37 All other chemicals were purchased 
from Sigma-Aldrich, unless otherwise indicated. 
 
2.3.2 Peptidoglycan glycosyltransferase (PGT) initial rate assays: 
(performed by Dr. Andrew Wang, Dr. Tania Lupoli, and Yihui Wu) 
 
In a typical PGT assay, PGT was incubated in reaction buffer (indicated below), and then 
[14C]- or [3H]-Lipid II was added to initiate polymerization. For preincubation experiments, 
Gal-Lipid II (1.2 μM) or Gal-Lipid IV (1.2 μM) was preincubated with reaction buffer and 
PGT for 20 minutes, and then [14C]- or [3H]-Lipid II was added to initiate polymerization. 
Reaction buffers were optimized for each PGT enzyme. For full length and TP truncated E. 
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coli PBP1A and PBP1B: 50 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (pH = 7.5), 10 mM CaCl2, 1000 units mL-1 penicillin G and 20% DMSO (v/v). For S. 
aureus PBP2: 50 mM CHES (N-Cyclohexyl-2-aminoethanesulfonic acid), 50 mM HEPES, 
50 mM acetic acid, 50 mM MES (2-(N-morpholino)ethanesulfonic acid) (pH =5), 10 mM 
CaCl2 and 20% (v/v) DMSO. For S. aureus SgtB: 12.5 mM HEPES (pH = 7.5), 2 mM 
MnCl2, 0.25 mM Tween-80, and 20% (v/v) DMSO. The reaction mixtures were incubated at 
room temperature for the time points specified. For the paper chromatography assay, reaction 
mixtures were quenched by mixing with an equal volume of 1 μM Moenomycin A in 10% 
Triton X-100 solution on ice. The mixtures were then spotted on 1 × 20 cm 3MM CHR 
chromatography paper strips (Whatman) before eluting with isobutyric acid/1M NH4OH 
(5:3, v/v). Starting material migrates on the strip, while polymer product remains at the 
origin. The paper strips were cut, immersed into EcoLite(+) liquid scintillation cocktail (MP 
Biomedical), and analyzed by a LS 6500 scintillation counter (Beckman Coulter). The 
percent radioactivity of the polymer product was calculated by comparing the amount of 
radioactivity that remains at the origin (peptidoglycan) to the total amount of radioactivity on 
the strip. The reaction rate was estimated from the initial linear range of each time course. 
The rate enhancement of Gal-Lipid IV preincubation was calculated by comparison with the 
normal Lipid II reaction (without Gal-Lipid IV). 
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2.3.3 SDS-PAGE Assay: 
(performed by Dr. Andrew Wang) 
 
E. coli PBP1A (600 nM) was incubated with and without Gal-Lipid IV (1.2 µM) for twenty 
minutes before the reaction was initiated with [14C]-Lipid II in the reaction mixture described 
above. Time points were quenched by heating samples for 5 minutes at 90°C at the various 
time points indicated. Gel electrophoresis analysis was carried out as described in Barrett et 
al. Briefly, samples were dried and resuspended in sample buffer (125 mM Tris-HCl (pH = 
6.8), 40% glycerol, 15% SDS (sodium dodecyl sulfate), 0.004% bromophenol blue) before 
being loaded onto a 20 × 20 cm gel (1 mm thick) and separated at 30 mA until the dye front 
was 1 cm from the bottom. Gels were dried overnight, and then exposed to a phosphorimage 
screen (GE Healthcare) for 1 week before being scanned using a Typhoon 9400 scanner (GE 
Healthcare). Radioactive bands were detected using the ImageQuant TL software package 
(GE Healthcare). 
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Chapter 3: A robust, high yielding preparation of monodisperse and monomeric SgtB 
for solution structural studies 
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3.1 Introduction 
Peptidoglycan glycosyltransferases (PGTs) transglycosylate Lipid II molecules to 
form peptidoglycan (PG).1 The availability of well-defined substrates has enabled a series of 
biochemical experiments from which a working model of PGT polymerization to be 
proposed.2 Briefly, the process is initiated by the uptake of two molecules of Lipid II by the 
PGTs to synthesize a nascent PG fragment, Lipid IV. In order for the PGT to elongate Lipid 
IV on its reducing end in a processive manner, the same Lipid IV molecule has to be 
translocated to the donor binding site so that another Lipid II molecule can bind as an 
acceptor. By performing multiple cycles of transglycosylation and translocation, the nascent 
PG is elongated in a processive manner to yield a glycan polymer of desired length before it 
is released. The studies presented in Chapter 2 demonstrate that the addition of Gal-Lipid IV 
abrogates an often observed initial lag-phase in the course of PG synthesis, providing a 
kinetic dimension to the model. Specifically, our evidence suggests that the synthesis of 
Lipid IV is the rate-limiting step, thus the addition of Gal-Lipid IV induces the enzyme to 
take on an “activated” elongation-competent state. Additionally, a recent study by Paradis-
Bleau, Markovski, Uehara, and coworkers identified an accessory protein LpoB from 
Escherichia coli that produces a similar “activation” effect with Escherichia coli PBP1B, 
providing further evidence that the PGTs can take on a distinct “activated” elongation-
competent state.3 Structural studies of PGTs (apo and Moenomycin A bound) have suggested 
that the lower lobe is floppy and some of these conformational dynamics may be important in 
performing its catalytic function.4,5,6,7,8 To date, there is no structural data that depicts how 
PG fragments interact with the PGT.  A structure of a Gal-Lipid IV bound PGT would enable 
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one to compare and contrast the differences in conformation, as well as changes in structural 
mobility between the apo and substrate-bound enzyme. 
Nuclear Magnetic Resonance (NMR) spectroscopy is the only structural technique 
that enables one to obtain a three-dimensional structure of a protein and quantitatively probe 
the conformational dynamics of the protein at an atomic-level without introducing additional 
structural perturbations.9,10 However, this structural technique requires an abundance of well-
behaved monodisperse protein that is stable at room temperature for a few weeks.11  
Assuming the target protein has a mass of 25 kDa, a typical 500 µL protein NMR 
sample at a concentration of 500 µM would require 6-7 mg of pure, isotopically labeled, 
monodisperse and monomeric protein. Assuming that we are able to recover 90% of the 
target protein at each processing step, a sample preparation methodology involving 5 
processing steps – immobilized affinity chromatography (IMAC), buffer exchange by 
dialysis, purification tag removal, size-exclusion chromatography, and final sample buffer 
exchange – would required the ability to obtain at least 10 mg of IMAC purified soluble 
protein. The material requirements are further elevated since proteins are often recombinantly 
expressed as a mixture of oligomers and well-behaved monomers, thus the practical 
implementation of a solution structural project would require access to at least 20 mgs of 
IMAC purified protein.12 Furthermore, large quantities of protein will be required for 
screening optimal buffer conditions that maximize protein stability and spectral resolution. 
The incorporation of isotopic labels (2H, 15N, 13C) can be prohibitively expensive and every 
effort has to be made to streamline processing and minimize waste.  
Chapter 3 presents the development of an efficient preparative method for obtaining 
sufficient quantities of our target PGT, the monofunctional glycosyltransferase SgtB from 
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Staphylococcus aureus. We are able to obtain upwards of 7 mg of monodisperse and 
monomeric SgtB protein with this preparation from one liter of LB culture, and 5 mg of 
monodisperse and monomeric SgtB protein from one liter of M9 minimal media culture. The 
method presented maximizes the protein throughput and recovery with each processing step 
and minimizes sample volume manipulation by centrifugal diafiltration. Because the method 
can be completed within a single day, it is possible to obtain 100 mg of well-behaved SgtB in 
a single week using common laboratory equipment. 
 
3.2 Results and Discussion 
 
3.2.1 Challenges of preparing large quantities of monodisperse and monomeric PGTs 
 
PGTs are membrane-associated enzymes which are difficult to prepare and handle 
because they are extremely prone to aggregation. Protein sequence hydrophobicity analysis 
suggested this might from two potential sites for nonspecific interaction: an N-terminal 
transmembrane anchoring helix and a second potential membrane association face.13,14 As a 
result, recombinantly expressed PGTs often form inclusion bodies or soluble aggregates even 
in the presence of detergent.15 Early strategies for isolating involved removing the N-terminal 
transmembrane helix anchor and attaching a GST solubility tag in its place.16,17,18 
Unfortunately, the isolated monomeric and monodisperse protein can quickly become 
polydisperse, forming soluble oligomers at higher concentrations, eventually resulting in 
precipitation even when stored at 4 oC.15 Despite these challenges, the first two crystal 
structures of PGT were presented in 2007, with another two published in 2009, including one 
presenting the transmembrane helix anchor.4,5,6,19,20 The structural data presented confirms 
the existence of a large hydrophobic surface that is situated at the base of the lower lobe of 
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the PGTs which presumably enables the enzyme to interact with the surface of the 
cytoplasmic phospholipid membrane bilayer. Additionally, the perceived structural flexibility 
of the PGTs may expose interaction sites or result in partially unfolded conformations that 
promote aggregation. 
 
 
3.2.2 Maximizing protein yield: lessons from the purification of Aquifex aeolicus PBP1A 
PGT 
We picked the Aquifex aeolicus PBP1A PGT ∆TM construct, aaPGT(51-243) as a 
starting point for developing a method for obtaining pure, monodisperse PGT protein. This 
was because prior research done by a former member of the group, Dr. Yanqiu Yuan on a 
series of aaPGT constructs put in place a protocol that gave pure, monodisperse, dimeric 
protein that was suitable for crystallographic analysis, albeit at low yields.21 
Dr. Yuan’s preparation of aaPGT(51-243) was an extension of Novagen’s cell lysis 
and protein extraction methodology, with the insertion of an additional extraction step in a 
buffer containing 1% (w/v) CHAPS detergent (3-[(3-Cholamidopropyl)dimethylammonio]-1- 
propanesulfonate) based buffer before the crude soluble protein extracts were loaded onto an 
Ni-NTA immobilized metal affinity chromatography (IMAC) column for a first-pass crude 
purification.22 This additional extraction step with the 1% (w/v) CHAPS buffer improved the 
yield of soluble protein that can be obtained from an overexpression culture by up to 2-fold. 
In my discussions with Dr. Yuan, while the existing process enabled her to produce pure, 
monodisperse protein for crystallographic work, the yield of protein per liter culture was low 
because a lot of protein was lost through the multiple centrifugal diafiltration process used to 
concentrate proteins throughout the preparation. 
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Our first objective was to minimize the loss of protein through centrifugal 
concentration because it is important to be able to manipulate the volume and concentration 
of a protein sample throughout its polishing process without suffering from a severe loss of 
material. Higher recoveries of protein from centrifugal concentration would dramatically 
boost yields from this process and enable the preparation of highly concentrated samples of 
isotopically labeled protein with minimal wastage.  
Previous research has shown that proteins can adhere non-specifically to the surface 
of ultrafiltration membranes resulting in reduced recovery yields.  At high g-forces, the 
centrifugal force and flow of solvent packs a very dense layer of protein against the 
ultrafiltration membrane, giving rise to an environment that promotes protein aggregation, 
unfolding and precipitation, resulting in fouling of the fine meshwork of the ultrafiltration 
membrane and low protein recovery.23 For proteins such as the PGTs which are inherently 
prone to aggregation, concentrating proteins by centrifugal diafiltration can result in protein 
aggregation and denaturation that depress recovery yields. 
A technique commonly used by bioprocessing community is to passivate the 
diafiltration membrane surface of the Amicon Ultra-15 centricon units by incubating it with a 
1% BSA solution or a dilute solution of detergent.24,25 Indeed, a combination of pre-treating 
the centricons with 1%(w/v) BSA solution, using a low centrifugal speed (max 1500×g) with 
frequent resuspensions to prevent the build up of protein material at the membrane interface 
between spins (every 20 minutes) allowed us to boost protein recoveries from 20% to 85-
90%. 
Our second objective was to obtain a concentrated stock of protein coming off the 
IMAC column by minimizing the volume of eluant required for releasing all the bound 
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protein. This will minimize the need to manipulate large volumes of dilute protein solution 
which is cumbersome to handle, and will require long downstream concentration times that 
inevitably will lead to protein loss from non-specific absorption when it comes in contact 
with large surfaces. We decided to optimize this process on two fronts – (1) minimize the 
amount of IMAC-resin used to pull-down and isolate the 6XHis-tagged protein, and (2) 
improve the efficiency of protein elution from the Ni-NTA resin by using a higher 
concentration of imidazole coupled with a very slow elution flow rate that allows the 
Imidazole to completely exchange with the 6XHis-tagged protein. Following the published 
protocol, the complete elution of aaPGT(51-243) requires 11 or more column volumes (CV) 
of elution buffer, yielding a dilute protein solution.5 By increasing the Imidazole 
concentration in the elution buffer from 200 mM to 500 mM, and allowing a 5 minute 
equilibration time before collection of each elution fraction, we were able to completely elute 
our protein using 3 CV. 
The downstream payoffs from utilizing this column concentration effect are 
numerous: (1) the removal of Imidazole by dialysis is more efficient because smaller dialysis 
cassettes can be used, minimizing material losses from non-specific absorption onto the 
membranes, (2) proteolytic cleavage of the solubility/purification tags will not require 
additional concentration steps to increase the protein substrate to protease ratio, and (3) both 
the number of Amicon Ultra-15 concentrators required for concentrating the protein for 
injection onto a size-exclusion chromatographic system as well as the amount of time in 
which the protein is exposed to centrifugal diafiltration are reduced. In all, minimizing the 
number of handling steps enabled us to maximize our protein yield from processing. Taken 
together, our improvements in the preparatory process of aaPGT(51-243) resulted in a 4-fold 
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improvement in the yield of monodisperse aaPGT(51-243) protein (3-4 mg/L from <1 mg/L) 
at existing protein expression levels. In the following section, we apply these strategies to 
optimizing the preparation of SgtB for solution structural work. 
 
3.2.3 SgtB as a candidate for solution structural studies 
In 2009, researchers at Pfizer published a high resolution crystal structure of 
Staphylococcus aureus monofunctional glycosyltransferase, SgtB bound to its natural 
inhibitor, Moenomycin A.20 We are interested in SgtB because it is one of the three PGTs 
present in the clinically relevant pathogen, Staphylococcus aureus.26 SgtB is a good model 
system for characterizing the PGT domain because it is a fully functional PGT that lacks a 
transpeptidase domain, and its small size (26.2 kDa) makes it amenable for NMR 
spectroscopy.27 In Chapter 2, we have also observed that SgtB displayed the largest rate-
enhancement effect when preincubated with Gal-Lipid IV, suggesting that we might be able 
to observe clear changes in its conformational state and dynamics when it binds Gal-Lipid 
IV. Because the PGTs are highly conserved across bacterial species, findings from the SgtB 
model system will bring insight into how the PGTs work as a class of enzymes.28 
Additionally, previous reports have suggested that SgtB can be isolated as a monomer in the 
presence of 0.7% (w/v) CHAPS detergent.27 Given that Pfizer had successfully obtained a 
crystal structure with an SgtB construct, we believed that obtaining sufficient quantities of 
well-behaved SgtB protein was within reach.  
Through a material transfer agreement with Pfizer, we were able to obtain the exact 
construct used for crystallographic studies by Pfizer: His6-TEVpc-SgtB(68-269). This was a 
∆TM(1-67) SgtB construct that was cloned into a pET15b equivalent vector, incorporating an 
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N-terminal Tobacco-etch virus (TEV) protease cleavage sequence (TEVpc) that allowed the 
swift removal of 6XHis purification tag. It is highly similar to previous SgtB constructs used 
for recombinant overexpression, differing only in the type of N-terminal protease cleavage 
sequence that facilitated the removal of the 6XHis tag (Figure 3.1).  
 
 
Figure 3.1 Various published SgtB overexpression constructs 
 
Unfortunately, despite our best efforts, we were unable to obtain large quantities of 
well-behaved SgtB using published protocols (Figure 3.2). In our personal communication 
with the Pfizer research team that crystallized SgtB, we learned that they minimized, and at 
times omitted the use of CHAPS detergent from their processing of the protein for 
crystallization. Our experience with SgtB suggested that the level of salts and CHAPS 
detergent used during processing by the Pfizer team would cause the protein to form soluble 
aggregates that cannot be disrupted by dilution (see Chapter 4, Figure 4.18). Our experience 
with aaPGT taught us that the use of CHAPS detergent was crucial to extracting and 
stabilizing the PGT during biomass processing and protein purification. We decided to apply 
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the same highly tuned process for preparing SgtB. We briefly delineate our optimized 
process for preparing sgtB in the section that follows. 
 
 
Figure 3.2 Purification of His6-TEVpc-SgtB(68-269) following Pfizer’s published protocol. 
Briefly, the protein is first purified by IMAC and subsequently by anion exchange 
chromatography. (a) SDS-PAGE gel of preparatory process. (b) Anion Exchange 
Chromatography, gradient elution of the protein by NaCl.    
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Figure 3.3 Purification of His6-TEVpc-SgtB(68-269) expressed in unlabeled M9 minimal 
media. following the methodology described in Section 3.2.4. (a) SDS-PAGE gel of the 
purification process. TCP: Total cell protein. S1: Novagen Bugbuster soluble extracts. S2: 
1% CHAPS buffer soluble extracts. E1: Ni-NTA IMAC purified His6-TEVpc-SgtB(68-269). 
E2: Ni-NTA IMAC purified His6-TEVpc-SgtB(68-269) from a different purification batch, 
showing consistency. M: Size-exclusion (Superdex 200) purified monomeric His6-TEVpc-
SgtB(68-269). (b) Preparatory size-exclusion profile of His6-TEVpc-SgtB(68-269).     
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3.2.4 A robust method for preparing large quantities of monodisperse and monomeric 
SgtB 
Upon lysis, SgtB rapidly degrades even in the presence of a large amount of broad-
spectrum protease inhibitors. We minimized lysis times which were important in preventing 
proteolytic degradation of the protein. We found that 10 mL of Bugbuster suspension is 
required for every 2 grams of biomass to enable efficient lysis within 15 minutes at 4oC. The 
supernatant is rapidly passed through a Ni-NTA column 3 times to saturate the resin with 
6XHis-tagged bound SgtB to minimize loading times and contact with proteases. Re-
extraction of the pellet with 1% CHAPS qualitatively allowed us to improve our yields by 
almost 2-fold. We optimized the biomass:Ni-NTA resin mass ratio which allowed us to 
minimize the number of wash steps during IMAC since a lower amount of resin would result 
in smaller amounts of impurities that are non-specifically bound to the resin. Once again, by 
using a small amount of resin with high concentration of Imidazole (500 mM), we were able 
to utilize the column concentration effect in IMAC to minimize the volume of the eluted 
SgtB protein sample. The immediate addition of CHAPS to a final concentration of 8 mM 
(~0.5% w/v) when the protein is eluted off IMAC retarded the spontaneous aggregation and 
precipitation of the protein prior to processing by size-exclusion chromatography (Figure 3.3 
and 3.4). In order to maximize the fraction of monomeric protein present in the protein 
sample that is loaded onto size-exclusion chromatographic system, we investigated the 
possibility of omitting the lengthy step of removing Imidazole by dialysis. Surprising, we 
found that high concentrations of Imidazole is crucial for slowing the formation of 
aggregates (Figure 3.5a and 3.5b). 
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Figure 3.4 Decrease in the relative abundance of monomeric His6-TEVpc-SgtB(68-269) after 
IMAC purification over time despite the addition of CHAPS detergent. Relative abundance 
of monomeric protein versus higher oligomers as measured by area under Abs(280nm) peaks 
from analytical size-exclusion profiles.  
 
 
 
Figure 3.5 Size-exclusion profiles of IMAC purified His6-TEVpc-SgtB(68-269). (a) Size-
exclusion profile of IMAC purified His6-TEVpc-SgtB(68-269) that was dialyzed overnight to 
remove imidazole. (b) Size-exclusion profile of IMAC purified His6-TEVpc-SgtB(68-269) 
that is immediately chromatographed. (c) Size-exclusion profile of IMAC purified His6-
TEVpc-SgtB(68-269) grown in unlabeled M9 minimal media.    
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In order to maximize the throughput on a 300 mL HiLoad 26/60 Superdex 200 size-
exclusion chromatographic system, we had to determine the total amount of protein we could 
load onto a 2 mL sample loop (largest sample loop available from the GE Healthcare AKTA 
FPLC series). We found that concentrating our IMAC purified SgtB beyond 15 mg/mL (~ 
570 µM) would decrease the chromatographic yield of monomeric protein because these high 
concentrations push the equilibrium towards the formation of soluble aggregates and 
precipitates. As a result, we have a maximum throughput of 30 mg (2 mL X 15 mg/mL) of 
IMAC purified SgtB for each chromatographic run which takes 4 hours to complete at a flow 
rate of 1.8 mL/min. Because 1 liter of LB culture yields 15 mg of IMAC purified SgtB, this 
implies 2 liters of LB culture (approximately 7 g wet biomass)   
Earlier on, our observation that the combination of 500 mM imidazole and 8 mM 
CHAPS retards but does not abrogate SgtB aggregation meant that the maximal amount of 
biomass that can be processed per day is limited at ~ 7g+ (2L of LB culture, 1L of M9/H2O 
culture, 0.5L of M9/D2O). Allowing IMAC-purified protein stock to stand in line for 4 hours 
for a subsequent chromatographic run would drastically decrease the yield of monomeric 
SgtB (Figure 3.4). 
In order to prepare isotopically labeled His6-TEVpc-SgtB(68-269), we applied the 
Marley method to expressing SgtB in M9 minimal media because it was a time and cost 
efficient way of producing isotopically labeled proteins for protein sample optimization.29 
We observed that the size-exclusion profile of the IMAC purified His6-TEVpc-SgtB(68-269) 
obtained from M9 minimal media expression as markedly different from that obtained from 
expression in LB media (Figure 3.5c). There was a greater proportion of protein that is 
monomeric – suggesting that the reduced growth and expression process in minimal media 
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may be better suited to producing His6-TEVpc-SgtB(68-269) that is correctly folded. This is 
in line with previous observations that expression yields of PBPs and PGTs are improved 
with late induction (OD600: 0.85-1.20) where cell growth rates are very slow.30 
In sum, expressing His6-TEVpc-SgtB in M9 minimal media, spiking the IMAC elution 
fractions with CHAPS and rapid processing with passivated centricons for size-exclusion 
chromatography allowed us to access large amounts of monomeric His6-TEVpc-SgtB(68-
269). A summary of all published methods for preparing SgtB is provided in the following 
page (Figure 3.6). 
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Figure 3.6 Summary of all published preparations of SgtB 
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3.3 Selected Methods and Materials 
 
3.3.1 Components of M9 minimal media  
(adapted from formulation courtesy of Dr. Alexander Koglin) 
 
All chemicals are purchased from Mallinckrodt Chemicals unless otherwise noted. 1.0 mL of 
1M MgSO4, 0.2 mL of 1M CaCl2, 0.2 mL of 1M FeCl3, 0.2 mL of Vitamin mix described 
below) and 80 µL of autoclaved glycerol are added to 500 mL of H2O and stirred vigorously. 
2.0 g of D(+)Glucose anhydrous (CalBioChem), 1.2 g of NH4Cl are added to the solution. 
200 mL of 5X M9 salt solution (described below) is added and stirred vigorously. The pH of 
the media is adjusted to 7.5, topped up with H2O to make 1000 mL and passed through a 
0.2micron filter. The media is made fresh and used immediately. Vitamin mix is prepared by 
mixing the following compounds purchased from Sigma-Aldrich in 15 mL of H2O: 0.4 g 
Choline Chloride (2-hydroxyethyl)trimethylammonium chloride), 0.5 g Folic acid ((2S)-2-
[(4-{[(2-amino-4-hydroxypteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid), 
0.5 g Pantothenic acid (3-[(2,4-Dihydroxy-3,3-dimethylbutanoyl)amino]propanoic acid), 0.5 
g Nicotinamide (pyridine-3-carboxamide) , 1 g Myo-inositol ((1R,2R,3S,4S,5R,6S)-
cyclohexane-1,2,3,4,5,6-hexol), 0.5 g Pyridoxal HCl (3-hydroxy-5-(hydroxymethyl)-2-
methylpyridine-4-carbaldehyde), 0.5 g Thiamin HCl (2-[3-[(4-Amino-2-methyl-pyrimidin-5-
yl)methyl]-4-methyl-thiazol-5-yl] ethanol), 0.05 g Riboflavin (7,8-Dimethyl-10-[(2S,3S,4R)-
2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione), 0.1g Adenosine ((2R,3R,4S,5R)-2-
(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol) and 0.1g Biotin (5-
[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoic acid). The vitamin 
mix is stored at -20 oC and away from light. The 5X M9 salt solution consist of 33.9 g 
Na2HPO4, 15.0 g KH2PO4 and 2.5 g NaCl in 1000 mL of H2O which is then passed through a 
0.2 micron filter. 
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3.3.2 Overexpression of His6-TEVpc-SgtB(68-269) in unlabeled M9 minimal media 
 
20 mL from a 50 mL Luria-Bertani (LB) with Ampicillin (10 µg/mL) overnight culture of 
BL(21)DE3 host cells carrying pET24b vector encoding His6-TEVpc-SgtB(68-269) is used to 
innoculate 2L LB with Ampicillin (10 µg/mL) culture. The 2L culture is grown at 37 oC for 
exactly 4.5 hours and harvested by centrifugation at 22 oC. The cell pellet is resuspended in 
200 mL of M9 salt buffer and centrifuged at 22 oC to remove the M9 salt wash buffer. The 
cell pellet is then resuspended in 1L of M9 media, with glucose as the carbon source and 
ammonium chloride as the nitrogen source. The M9 culture is then grown for 1.5 hours at 37 
oC before induction with 0.1 mM IPTG and allowed to grow at 37 oC for 6 hours. The culture 
is harvested by centrifugation at 4 oC to obtain 8 grams of wet biomass which is then stored 
as two 4 gram pellets at -80 oC. 
 
3.3.3 Purification of His6-TEVpc-SgtB(68-269) 
Each 4 gram pellet of wet biomass is thawed on ice for 2 hours and thoroughly resuspended 
in a mixture of 20 mL of Bugbuster (Novagen) lysis buffer and 1 mL of EDTA-free Protease 
Inhibitor Cocktail III (Novagen) over a course of 15 minutes on ice. 10 µL of Benzonase 
(Novagen) and 10 µL of rLysozyme (Novagen) is added to the resuspended biomass and the 
mixture is stirred at 4 oC for 20 minutes. The cell lysate is then centrifuged at 16000 × g, 4 oC 
for 35 minutes to obtain a clarified supernatant crude protein extract S1, taking care not to 
disturb the viscous emulsion that lies on the interface of supernatant and the pellet. 20 mL of 
pre-chilled 1% CHAPS (Anatrace) extraction buffer (20 mM Tris pH 7.5, 500 mM NaCL, 16 
mM CHAPS, 5 µL of Benzonase, 5 µL of rLysozyme) is used to resuspend the pellet along 
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with the viscous emulsion for 20 minutes. In the meantime, S1 is passed through an IMAC 
column (charged with 2 mL settled bed volume of Ni-NTA resin and pre-equilibrated with 10 
mM Imidazole IMAC Buffer) 3 times at a flow rate of 1 mL/min. The pellet emulsion extract 
is centrifuged for 35 minutes at 16000 × g, 4 oC to obtain a clarified supernant S2. S2 is 
immediately loaded onto the IMAC column charged with Ni-NTA resin at a flow rate of 0.3 
mL/min. The IMAC column is washed with 12 mL of 10 mM Imidazole IMAC buffer, 
allowing the buffer to run to the top of the resin before washing with 24 mL of 10 mM 
Imidazole IMAC buffer. Subsequently, the IMAC column is washed with 12 mL of 60 mM 
Imidazole IMAC buffer, allowing the buffer to run to the top of the resin before washing 
with 48 mL of 60 mM Imidazole IMAC buffer. 315 µL of 10% CHAPS (w/v) solution is 
added to a 50 mL Falcon tube to be used a collection receptacle for the IMAC-purified SgtB 
protein. 2 mL of 500 mM Imidazole IMAC buffer is added to the IMAC column and 
collected immediately as the first elution fraction. Another 2 mL of 500 mM Imidazole 
IMAC buffer is added the IMAC column and incubated with the resin for 5 minutes before 
collecting the elution at a flow rate of 0.3 mL/min to give the second elution fraction. This 
incubation-elution process is repeated once more to yield the third elution fraction. All three 
elution fractions are combined and concentrated immediately in a passivated Centricon 
(Amicon MWCO 10K) at 1500 × g, 4 oC for approximately 15 minutes to give a 2 mL 
protein stock (~15 mg/mL) that is loaded onto a HiLoad 26/60 Superdex 200 size-exclusion 
column without delay. The protein is chromatographed at a flow rate of 1.8 mL/min to yield 
14 mg of pure, monodisperse, and monomeric His6-TEVpc-SgtB(68-269). IMAC buffer is 
defined as 20 mM Tris, 500 mM NaCl, with the specified concentration of Imidazole. This 
entire purification process can be easily accomplished within 10 hours/1 workday. 
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Chapter Four: Development of an SgtB sample for NMR spectroscopy 
 
 
 
 
 
 
 
 
 
 
 
 
The work presented in this chapter is a result of a collaboration between the Kahne, Walker 
and Wagner research groups at Harvard Medical School. Protein biochemistry was 
performed by Yihui Wu (Kahne). Spectroscopic data acquisition was performed by Dr. 
Ricard Rodriguez-Mias (Wagner) and Dr. Haribabu Arthanari (Wagner).  
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4.1 Introduction 
In 2007, Strynadka et. al. solved both the ligand-free and Moenomycin A-bound 
crystal structure of the Staphylococcus aureus PBP2 (saPBP2).1 Their efforts provided the 
first structural insight to the conformational changes that may occur when the only known 
natural inhibitor of the peptidoglycan glycosyltransferases (PGT), Moenomycin A (MmA) 
forms a tight non-covalent interaction with the enzyme. MmA has been proposed to be a 
competitive inhibitor of the polymeric product of the PGT (Lipid IV and longer 
peptidoglycan fragments) because of the similarities in chemical structure between MmA and 
Lipid IV.2  Recent kinetic data supports this view that MmA binds to the donor-site of the 
PGT as preincubation with Gal-Lipid IV, a known donor-site specific binder increases the 
IC50 of MmA by 5 fold in Escherichia coli PBP1a.3 The enzymological studies detailed in 
Chapter 2 show that Gal-Lipid IV is able to enhance the initial rate of PG synthesis, possibly 
by inducing a conformational change on the PGT.4 As a result, we were intrigued by the 
large conformational difference between the apo and the MmA-bound structure of saPBP2 in 
the lower lobe region (also called “jaw” region) because it may suggest a structural 
mechanism of how the PGT is activated for peptidoglycan (PG) biosynthesis.5,6,7,8,9  
Given this backdrop, we were motivated to obtain a Nuclear Magnetic Resonance 
(NMR) solution structure of a PGT with Gal-Lipid IV from Staphylococcus aureus for 
several reasons: (1) it would enable us to visualize the structure and analyze the 
conformational dynamics that are involved in the activation of the PGT enzyme derived from 
the clinically relevant Staphylococcus aureus pathogen, (2) comparing the structure of Gal-
Lipid IV bound PGT with a the existing MmA bound PGT structures would bring 
mechanistic insight on how MmA inhibits the function of the PGT, and (3) structural 
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information on how various ligands, such as Lipid II or a new inhibitor/probe interact with 
the PGT can be quickly deciphered by titrating the NMR protein sample with the ligand of 
interest, without having to redevelop crystallization conditions for each protein:ligand 
complex. 
PGTs are a challenging class of proteins to work with because of their conformational 
flexibility and its amphiphilic structural properties that come with being a membrane-
associated protein.10 Successful overexpression and purification of soluble PGTs often 
require the removal of the hydrophobic transmembrane helix anchor (∆TM).11,12,13,14,15 
However, the PGTs still possess a large hydrophobic surface situated at the base of its lower 
lobe that allows the protein to interact with the cytoplasmic membrane (Figure 4.1) that 
causes it to form soluble aggregates that are difficult to disperse.16,17 As a result, a small 
monofunctional PGT such as the 26.2 kDa ∆TM SgtB can form dimers and higher oligomers 
with a molecular mass upwards of 52 kD (not including the mass of the bound detergent 
micelle which can contribute significantly to the final mass) that would make the protein 
intractable for solution structural work by NMR. 
 In Chapter 3, we developed a robust method for obtaining multi-milligram quantities 
of SgtB that is monodisperse and monomeric. In Chapter 4, we observed that the SgtB 
construct, His6-TEVpc-SgtB(68-269) becomes polydisperse and aggregates at concentrations 
relevant for solution NMR work (250 µM and up). To improve the stability of the protein 
construct at high concentrations, further investigations into buffer conditions, construct 
redesign and the addition of solubility-enhancement tags are needed. This chapter presents 
the systematic development of an SgtB protein sample that is amenable for solution structural 
work by NMR. 
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Figure 4.1 Amphiphilic structural properties of the PGTs. The upper lobe (grey) is displays a 
mostly hydrophilic surface whereas the lower lobe (blue) has a sticky hydrophobic patch that 
contacts the cytoplasmic membrane.  
 
4.2 Results and Discussion 
4.2.1 Initial foray with SgtB construct: His6-TEVpc-SgtB(68-269) 
 The overarching goal of this exercise is to develop a ligand-free sample of SgtB that 
is well-behaved and stable at the high concentrations and the extensive room temperature 
exposure required for solution structural studies. Any ligand of interest, e.g. Gal-Lipid IV can 
be added to this stabilized SgtB protein sample to produce a protein-ligand complex for 
spectroscopic analysis. The ligand-free SgtB can then serve as a standard for comparing the 
perturbations caused by the ligand of interest. 
We began our journey by investigating the feasibility of solution structure work on 
the His6-TEVpc-SgtB(68-269) construct. We chose His6-TEVpc-SgtB(68-269) construct as 
our starting point because we were able to prepare multimilligram quantities of SgtB using 
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this construct through an efficient, high yielding protocol which has the added benefit of 
being able to incorporate NMR-active isotopic labels through a minimal media expression 
system.18 Our preparation method gives us access to at least 7 milligrams of isotopically-
labeled (15N) His6-TEVpc-SgtB(68-269) protein that is required for preparing a fresh 500 µL 
protein sample at concentration of 500 µM in a single operation for spectroscopic 
measurements: 7-8 g wet biomass from 1 liter of 15N-M9 minimal media culture yields 
approximately 10 mg of monodisperse and monomeric His6-TEVpc-SgtB(68-269). 
 Protein fingerprinting by recording [1H,15N]-HSQC spectra is the gold-standard test 
on the feasibility of pursuing solution structure work because having sufficient spectral 
dispersion and peak count suggests that (1) the individual amide peaks are assignable, and (2) 
the protein was well-behaved at high concentrations - the protein is folded and does not form 
large soluble aggregates with extensive exposure at room temperature.19 Our first objective 
was to obtain a [1H,15N]-HSQC spectra of His6-TEVpc-SgtB(68-269) so that we can map out 
possible improvements and changes that can be made with the sample going forward. 
 The protein sample for NMR spectroscopy is ideally buffered by agents that are 
transparent to the spectrometer - free of carbon and nitrogen atoms, and be at an acidic pH 
(<7.0) so as to minimize the exchange of the amide backbone hydrogen with the bulk water 
solvent which reduces the number of visible peaks.20 The His6-TEVpc-SgtB(68-269) protein 
sample prepared using our protocol is not appropriately buffered for spectroscopic 
measurements. Our sample buffer contained a basic carbon-based buffer (20 mM Tris 
buffered at pH 7.5), a high concentration of CHAPS detergent (8 mM) that will contribute a 
strong N-H signal right in the middle of fingerprint spectral window and plenty of salt (500 
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mM NaCl) that will lead to longer 90o-pulse lengths, sample heating and poorer signal-to-
noise ratios, especially with modern cryogenic probes.21    
 In order to prepare our sample for this initial fingerprinting, we chose to focus on 
finding an optimal acidic pH that would confer reasonable stability to the protein for the 
duration of a 2-3 hour HSQC experiment (inclusive of time required for pulse sequence and 
water signal suppression optimization). We were less concerned with the amount of salt in 
the sample because the recent development of a salt-tolerant cold-probe as well as specially 
configured sample tubes presented an effective solution towards improving spectral 
resolution on a lossy sample.22,23,24 The CHAPS detergent did not present a serious 
impediment to obtaining solution structures of Calcineurin B and eFI4E through the 
application of isotope-edited pulse sequences minimized the interfering detergent 
signals.25,26,27  
 We tried to identify the optimal acidic pH that stability as judged by the amount of 
precipitated protein formed from dialysing a 300 µM sample of His6-TEVpc-SgtB(68-269) 
into a series phosphate buffers with a pH ranging from 5.0 to 7.2 at room temperature. We 
were hoping to identify a pH and a buffering agent which would result in no precipitation of 
the protein. The predicted pI of His6-TEVpc-SgtB(68-269) is 6.87 (ProtParam, ExPASY 
Server) which suggests that a pH lower than the pI, i.e. one or two units less than 6.87 might 
result in greater stability due to greater solubility from an increased net charge.28 
Unfortunately, all our samples contained precipitates - albeit to different extents. In fact, 
samples dialyzed into buffers at a lower pH resulted in more precipitation than those at a 
higher pH. We singled out a buffer containing 20 mM NaPi pH 6.8 because it was the most 
acidic buffer that had the least amount of precipitate as judged by eye. Analytical size-
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exclusion analysis of the soluble fraction in our most acidic sample (NaPi pH 6.8) showed 
that the majority of soluble protein (>70%) exists as a monomer, with a small fraction 
forming small oligomers. We reasoned that the amount of monomeric protein present in this 
sample might yield sufficient signal to give us an initial [1H,15N]-HSQC fingerprint of the 
protein that can guide construct and buffer optimization going forward. 
 We managed to prepare 1000 µL of a 300 µM sample of His6-TEVpc-SgtB(68-269) - 
8 mg of isotopically labeled protein in all - using our existing protocol which had the added 
step of a final buffer exchange facilitated by a PD-Minitrap G25 Sephacryl column (GE 
Healthcare) that acidified the pH from 7.5 to 6.8 while introducing D2O into the sample as a 
lock component (5% v/v). The PD-Minitrap G25 Sephacryl column was pre-equilibrated 
with the final NMR buffer of 20 mM Sodium Phosphate (NaPi), 500 mM NaCl, 8 mM 
CHAPS and 5% (v/v) D2O before use. We split the sample in two: one half was used to 
obtain a [1H,15N]-HSQC spectra, and the other half was used to obtain a size-exclusion 
profile of the sample to determine the aggregation state of the sample being measured over 
time.  
 The [1H,15N]-HSQC spectra was acquired using the fastHSQC (fHSQC) pulse 
sequence: a flip-back WATERGATE-HSQC sequence that does not require extensive 
calibration, minimizing the time between sample loading and spectral acquisition.29 As a 
result, we were able to rapidly obtain a spectra of His6-TEVpc-SgtB(68-269) with minimal 
exposure time to room temperature conditions in the spectrometer. However it displayed 
poorly resolved, poorly dispersed, and broadened peaks (Figure 4.2). These features are 
characteristic of protein sample that might be either partially unfolded, are undergoing an 
aggregation process of forming larger oligomers, or both. Subsequently, using the same 
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sample, we acquired a [1H, 15N]-HSQC spectra using the TROSY pulse sequence which is 
designed to improve spectral resolution and sensitivity with larger protein masses.30,31 The 
TROSY-HSQC spectra showed a slight improvement in dispersion, but was nonetheless 
poorly resolved and poorly dispersed, an indication that our protein was forming an 
aggregate. The analytical size-exclusion profile of the sample over the course of the HSQC 
measurement indicated that the protein was steadily accumulating higher oligomers that 
cannot be broken down through the dilution effect of the size-exclusion chromatography 
(Figure 4.3). A possible explanation for this observation might be that the flexible end 
regions of the protein such as the N-terminal His6-TEVpc appendage (21 amino acids long) 
drive a nonspecific interaction that results in the formation of aggregates. If this were true, 
clipping off the His6-TEVpc appendage might separate the individual monomers within the 
aggregate and prevent the formation of oligomers at high concentrations.  
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Figure 4.2 Initial [1H,15N]-HSQC spectra of His6-TEVpc-SgtB(68-269). (a) Spectra acquired 
with fHSQC pulse sequence. (b) Spectra acquired with TROSY pulse sequence. 
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Figure 4.3 Analytical size-exclusion profile of the NMR sample of His6-TEVpc-SgtB(68-
269) at a concentration 300 µM, in the presence of 20 mM NaPi, 500 mM NaCl, 8 mM 
CHAPS, 5% (v/v) D2O.  
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4.2.2 SgtB(68-269), sans His6-TEVpc appendage 
 To test our hypothesis, we took the existing aggregated His6-TEVpc-sgtB(68-269) 
NMR sample and digested it with a 6XHis-tagged TEV pretease which clipped off the His6-
TEVpc appendage.32 The TEV protease and His6-TEVpc appendage were removed by 
repeated passage (3X) of the digestion reaction mixture through a Ni-NTA based 
immobilized metal affinity chromatography (IMAC) column to yield pure SgtB(68-269) 
(Figure 4.4). The size-exclusion profile indicated that we manage to recover most of our 
protein as free monomers, firming up our suspicion that the His6-TEVpc appendage was 
indeed contributing to the aggregation behavior of our protein. However, when we 
concentrated up the digested SgtB(68-269) sample which was diluted by size-exclusion 
chromatography, we obtained a poorly dispersed [1H,15N]-TROSY HSQC spectrum 
indicating the protein sample at high concentrations was either partially unfolded or 
aggregated (Figure 4.5). Although the His6-TEVpc appendage contributed aggregation 
behavior, there were probably other sites that can form nonspecific interactions. 
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Figure 4.4 Removal of His6-TEVpc appendage from His6-TEVpc-SgtB(68-269). (a)( i) Size-
exclusion profile of His6-TEVpc-SgtB(68-269) after 1 day of NMR measurements is digested 
with TEV protease and purified by Ni-NTA IMAC chromatography. The product, SgtB(68-
269) is polished by size-exclusion chromatography (ii) to remove traces of His6-TEVpc-
SgtB(68-269) aggregates. (b) Lane 1: TEV protease, Lane 2: His6-TEVpc-SgtB(68-269) after 
NMR measurements, Lane 3:TEV protease digestion product of His6-TEVpc-SgtB(68-269) = 
SgtB(68-269), and Lane 4: Purified SgtB(68-269).  
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Figure 4.5 [1H,15N]-TROSY HSQC spectrum of SgtB(68-269) after removal of the His6-
TEVpc appendage.  
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4.2.3 Introducing a high affinity ligand: Moenomycin A bound His6-TEVpc-SgtB(68-
269) 
 We had several options ahead of us to prevent aggregation in the sample: (1) identify 
a buffer composition that would stabilize interactions within the protein that keep it well-
folded while destabilizing unfavorable protein-protein interactions, and (2) adding solubility-
enhancement tags that can act as a shield against unfavorable protein-protein interactions 
while modulating the electrostatic and hydration properties of SgtB. Alternatively, we could 
use a high affinity ligand that possibly locks the protein into one conformational state and 
prevents it from sampling states that are aggregation-prone. Although we would not be able 
to obtain solution structural information on the apo-state of SgtB, we could still obtain 
solution structural information on a broad variety of tight binding ligands of interest e.g. new 
PGT inhibitors, PG fragments. 
 We opined that the addition of a high affinity ligand would enable us to make the 
biggest advance in terms of structural stability because locking the protein into one 
conformational state would prevent it from sampling states which lead to aggregation. Two 
candidates immediately stand out: Gal-Lipid IV and MmA. Previous work within the Kahne 
research group has suggest that Lipid IV binds tightly to the PGTs.33 Additionally, in Chapter 
2, we have shown that Gal-Lipid IV possibly induces a conformational change in the PGT 
that enhances the initial rate of PG synthesis. Introducing Gal-Lipid IV at this point would 
expedite the development of a Gal-Lipid IV bound SgtB sample for solution structural 
studies. However, this is not a viable solution because we did not have access to the 
approximately 1-3 mg of Gal-Lipid IV needed to test this strategy (a new robust synthetic 
route towards Lipid IV is being developed within the Kahne research group). We decided to 
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test this strategy with MmA, since we worked out a well-honed protocol access to hundreds 
of milligrams of pure MmA. MmA derivatives with shorter lipid moieties (C10, C15) can also 
be prepared in multimilligram quantities.34,35 
In contrast, the addition of a solubility-enhancement tag would require the 
construction of new expression vectors, possibly with new methods of overexpression and 
purification. Exhaustive buffer screening, while immediately feasible, will be laborious with 
no obvious starting point given the infinite combinations of detergent, salts and buffers. 
 We prepared a 1.0 mL partially deuterated (to take advantage of the TROSY effect), 
15N-labeled sample of His6-TEVpc-SgtB(68-269) at 350 µM.36 We then split the sample in 
two and added an excess amount (~5 equivalents) of C15-(Z,E)-Farnesyl-MmA to one half of 
it. We used C15-(Z,E)-Farnesyl-MmA because its shortened lipid tail gave it better solubility 
properties in aqueous media than Moenomycin A (Figure 4.6).  
The difference between the [1H,15N]-TROSY HSQC spectra obtained from the 
liganded versus ligand-free protein samples showed that the addition of C15-(Z,E)-Farnesyl-
MmA resulted in a vast improvement in spectral dispersion and peak count (Figure 4.7). 
Improved sample stability due to the addition of C15-(Z,E)-Farnesyl-MmA was also observed 
from the greatly reduced amount of precipitated protein in the NMR sample with C15-(Z,E)-
Farnesyl-MmA in contrast to the ligand-free sample. However, although the peak dispersion 
observed in the spectra was encouraging, there were insufficient peaks in the spectra for us to 
proceed with investingating the feasibility of obtaining a full spectrum assignment. The 
amount of precipitated protein was still significant and more had to be done to improve the 
stability of the protein sample. 
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Figure 4.6 Moenomycin A and its derivatives. (a) Moenomycin A. (b) Moenomycin A 
derivative with a shortened lipid tail: C15-(Z,E)-farnesyl-Moenomycin A. Shortened lipid 
derivatives of Moenomycin A possess an IC50 on the PGTs that is similar to Moenomycin 
A.38  
81 
 
 
Figure 4.7 [1H,15N]-TROSY HSQC spectra of partially deuterated 15N-labeled His6-TEVpc-
SgtB(68-269) with and without the Moenomycin A derivative, C15-(Z,E)-farnesyl-
Moenomycin A. (a) [1H,15N]-TROSY HSQC spectrum of His6-TEVpc-SgtB(68-269) with 
C15-(Z,E)-farnesyl-Moenomycin A added, and image of protein sample after measurement. 
(b) [1H,15N]-TROSY HSQC spectrum of ligand free His6-TEVpc-SgtB(68-269), and image of 
protein sample after measurement. Note the copious amounts of precipitated protein.  
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4.2.4 Incorporation of the solubility-enhancement tags, GB1 
The use of Streptococcal protein G domain 1 (GB1) solubility enhancement tags has 
been used by numerous research groups to improve the stability and solubility protein 
samples that were otherwise intractable for solution structural work.37 The GB1 solubility 
enhancement tag's key advantage over other solubility enhancement tags such as Thioredoxin 
protein (Trx), Maltose-binding protein (MBP), and Glutathion S-transferase (GST) 
commonly available in overexpression vectors is its small mass: one can incorporate 2 GB1-
tags to solubilize a passenger protein, adding only a modest 12.4 kDa to the overall mass of 
the fusion protein.38 Furthermore, the GB1 tags are available in an acidic (GB1A, pI = 4.6) 
and basic form (GB1B, pI = 8.0) that can be appropriately matched to the pI of the protein to 
maintain the optimal charged state for solubility. Based on the crystal structure of SgtB 
(PDB: 3HZS), the protein has a hydrophobic, membrane-interacting surface that is located 
near the N-terminus, which is in close proximity to the site where the transmembrane helix 
anchor would be connected. In an aqueous environment, these hydrophobic surfaces might 
have a high tendency to form nonspecific interactions, giving rise to large oligomeric 
complexes that eventually precipitate from solution. The addition of a GB1-solubility 
enhancement tag on the N-terminus of SgtB could mitigate this problem by shielding this 
hydrophobic surface. 
We screened a series of SgtB constructs incorporating acidic and basic variants of the 
GB1-tag on the N-terminus of the protein and identified a construct, His6-GB1A-SgtB(64-
269), an N-terminal 6XHis acidic GB1-SgtB fusion that produced the highest amount of 
soluble protein in M9 minimal media. Subsequently, we prepared a partially deuterated, 15N-
labeled sample of this construct at a concentration of 250 µM and supplemented it with 1.3 
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equivalents of MmA. The [1H,15N]-TROSY HSQC spectra presented the characteristic 
fingerprint of the GB1-tag, and there was no dispersion of the SgtB amide backbone 
hydrogen peaks (Figure 4.7a and 4.8). We were surprised that we did not even observe the 
same levels of dispersion despite the addition of MmA which we had previously observed to 
provide structural order to the protein. The only improvement we observed was the vast 
improvement in the solubility of the sample. After 12 hours of exposure at room temperature 
and in the presence of 1.3 equivalents of MmA, the His6-GB1A-SgtB(64-269) construct 
produced far lesser amounts of precipitated protein compared with His6-TEVpc-SgtB(68-
269). This suggests that the GB1 tag improved the overall solubility of the sample. We 
performed an enzyme activity test on His6-GB1-sgtB(64-269) and determined that the 
enzymatic domain of the fusion protein is active, hence the tag did not result in misfolding of 
SgtB.  
One possible explanation for the sum of these observations is the SgtB passenger 
protein aggregated whereas the GB1-tag remained dynamically free since it is attached to the 
flexible N-terminal segment of the protein. The observed peak broadening of the GB1 
associated peaks in the HSQC spectra might result from being attached to the large 
aggregated mass of SgtB influencing the overall tumbling of the fusion protein. Given that 
SgtB might interact with other cell-wall remodeling proteins present in the periplasm, the C-
terminal face of SgtB may have surfaces that facilitate protein-protein interaction. The 
addition of a second GB1-tag on to the C-terminus might shield these sticky surfaces and 
prevent the formation of aggregates.  
We identified a construct, His6-GB1A-SgtB(64-269)-gly-GB1A that incorporates a 
glycine spacer between the C-terminus of the SgtB protein and the acidic GB1 solubility tag 
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that produced soluble protein in M9 minimal media. We were able to prepare a partially 
deuterated, 15N-labeled sample of it at 250 µM for spectroscopic characterization in the 
presence of MmA. Again, we did not observe good dispersion of the amide backbone 
hydrogen peaks from SgtB in the HSQC spectra of this 38.6 kD fusion protein construct 
(Figure 4.7b). Similar to the single N-terminally GB1-tagged SgtB construct, the protein 
sample remained soluble as there were only minute amounts of precipitate. Given that the use 
of GB1-solubility enhancement tags together with the addition of MmA did not improve the 
peak count and peak dispersion in the [1H, 15N]-TROSY HSQC spectrum, we decided to 
forgo the use of solubility enhancement tags to improve protein stability at high 
concentrations.  
  
85 
 
 
Figure 4.8 [1H,15N]-TROSY HSQC spectra of GB1-tagged SgtB. (a) [1H,15N]-TROSY 
HSQC spectrum of partially deuterated, 15N-labeled His6-GB1A-SgtB(64-269) with 1.2 
equivalents of Moenomycin A added, and image of protein sample after measurement. (b) 
[1H,15N]-TROSY HSQC spectrum of partially deuterated, 15N-labeled His6-GB1A-SgtB(64-
269)-gly-GB1A with 1.2 equivalents of Moenomycin A added, and image of protein sample 
after measurement. 
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Figure 4.9 Characteristic [1H,15N]-HSQC spectra of 1 mM His6-GB1A (prepared by Dr. 
Ricard Rodriguez-Mias, Wagner group).  
 
 
Figure 4.10 Limited proteolysis of His6-TEVpc-SgtB(68-269) in the presence and absence of 
Moenomycin A by Subtilisin A. Lane 1: His6-TEVpc-SgtB(68-269) standard before Subtilisin 
A digestion, Lane 2: 1 hour digestion product of His6-TEVpc-SgtB(68-269) without 
Moenomycin A added, and Lane 3: 1 hour digestion product of His6-TEVpc-SgtB(68-269) 
with Moenomycin A added.     
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4.2.5 Optimizing the MmA bound His6-TEVpc-SgtB(68-269) sample: Limited proteolytic 
analysis with Subtilisin A  
We redoubled our efforts on the His6-TEVpc-SgtB(68-269) construct because  it gave 
us our most promising [1H,15N]-TROSY HSQC spectrum thus far. We prepared the 
inactivated mutant His6-TEVpc-SgtB(68-269) E100Q because we were interested in 
optimizing a construct would enable us to analyze reactive PGT substrates in a static enzyme 
system. We knew that the addition of a high affinity ligand Moenomycin A improved the 
peak dispersion of the sample by bringing more structural order to the protein as seen from 
the improved chemical shift dispersion of the spectrum. We wanted to see if it was possible 
to remove segments of the protein that remain disordered in the presence of Moenomycin A 
that may promote aggregation by limited proteolytic analysis.39,40 
Proteolytic digestion of His6-TEVpc-SgtB(68-269) E100Q with the nonspecific 
protease Subtilisin A in the presence of 1 equivalent of MmA at a protein concentration of 40 
µM yielded a stable protease-resistant fragment at 23-24 kDa (Figure 4.10). We analyzed 
this fragment by N-terminal Edman sequencing and ESI-MS and determined it to be 
SgtB(68-269) E100Q: it turns out that it is the very same fragment that would have been 
obtained from the removal of the His6-TEVpc appendage from His6-TEVpc-SgtB(68-269) 
E100Q by the TEV protease. In the absence of MmA, we did not obtain a protease resistant 
fragment when His6-TEVpc-SgtB(68-269) E100Q was digested with Subtilisin A. Taken 
together, MmA appears to tighten the fold of the protein such that a non-specific protease 
such as Subtilisin A is unable to efficiently digest the protein by acting on a segment of the 
protein that is poorly structured.  
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4.2.6 Preserving the monomeric state by adding MmA at low protein concentrations 
The fact that SgtB(68-269) E100Q turns out to be the stable core fragment surprised 
us because our earlier [1H,15N]-TROSY HSQC spectra of SgtB(68-269) suggested that the 
protein was aggregated at high concentrations (300 µM). We wondered whether the simple 
addition of MmA to the 300 µM sample of SgtB(68-269) E100Q would inhibit aggregation. 
Tracing the steps involved in preparing the 300 µM sample of SgtB(68-269) mentioned in 
section 4.2.2, we observed that SgtB(68-269) protein used to prepare the highly concentrated 
sample was monomeric and monodisperse as seen from its size-exclusion profile. The protein 
concentration after size-exclusion chromatography was 10-20 µM. This suggests that the 
formation of aggregates must occur at some point between the pooling and concentrating of 
fractions after size-exclusion chromatography to the act of acquiring the [1H,15N]-TROSY 
HSQC spectrum. To investigate this, we prepared two identical samples of SgtB(68-269) 
E100Q at a protein concentration of 550 µM from freshly prepared 20 µM monomeric stock 
of SgtB(68-269) E100Q (Figure 4.11). The first sample was immediately loaded onto a size-
exclusion column for profiling, while the second sample was stored at 4 oC for one hour 
before analytical profiling on a size-exclusion column. In the first sample, we observed the 
formation of small amounts of high molecular weight aggregates that cannot be broken apart 
by the dilution process of size-exclusion chromatography.41 In the second sample, we 
observed that these high molecular weight aggregates have increased proportion over the 
monomeric population. Taken together, these results show that the aggregates form as soon 
as the SgtB(68-269) E100Q protein is concentrated up from the pooled monomeric fractions. 
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Figure 4.11 Analytical size-exclusion profile of SgtB(68-269) at prepared at various protein 
concentrations. (a) SgtB(68-269) at 80 µM, (b) SgtB(68-269) concentrated from 80 µM to 
550 µM and profiled immediately, and (c) SgtB(68-269) concentrated from 80 µM to 550 
µM, incubated at 4 oC for 1 hour before profiling. 
  
 In order to prepare a monomeric, monodisperse sample of SgtB(68-269) E100Q at 
high concentrations, one must find an additive that preserves the monomeric state of the 
protein at a dilute concentration immediately after the removal of the His6-TEVpc appendage 
before proceeding with the sample concentration step. Thus far, we have learned that MmA 
is able to (1) enforce structural order on SgtB that resulted in a dispersed [1H,15N]-TROSY 
HSQC spectra and the identification of a protease resistant core and (2) improve the 
solubility of the protein by preventing precipitation from aggregation. We hypothesized that 
if we add MmA to SgtB(68-269) E100Q immediately after the removal of the His6-TEVpc 
appendage while the protein sample is still dilute and monomeric, we can lock the enzyme in 
a conformation that does not aggregate. The MmA bound SgtB(68-269) E100Q protein can 
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then be concentrated to the desired level required for NMR analysis, preserving the 
monomeric state throughout the final processing steps.  
In our collective experience of preparing various samples of SgtB, we observed that 
the protein remained monodisperse and monomeric at concentrations below 80 µM. 
Specifically, our proteolytic digestion analysis of His6-TEVpc-SgtB(68-269) E100Q in the 
presence of MmA was performed at 40 µM. We decided to prepare a solution of SgtB(68-
269) E100Q at 80 µM that would be mixed with an equal volume of buffer containing 1.3 
equivalents of MmA, bringing the final concentration of the protein species in the mixture to 
40 µM. The mixture is incubated at 4oC with gentle rocking for 3 hours. The entire operation 
is carried out at a buffered pH of 7.5 because the enzymatic function of SgtB has been 
previously found to be optimal in a slightly basic medium. We were able to concentrate our 
sample at 4oC to a final concentration at 600 µM without any protein material precipitating.  
 
4.2.7 Heat as a polishing step: exposing the protein sample to ambient room 
temperature 
We tested the heat susceptibility of our sample by incubating for 24 hours at ambient 
room temperature (22 oC). After 12 hours of exposure at room temperature, we observed that 
some of the protein was beginning to precipitate from solution. We monitored the protein 
concentration remaining in solution over several days and observed that the protein 
concentration had stabilized at approximately 450 µM after 72 hours of exposure at room 
temperature (Figure 4.12a). Analytical size-exclusion analysis of the protein fraction that 
remained solvent showed that the soluble protein was monodisperse and appeared to be 
monomeric. We tracked the soluble protein concentration and size-exclusion profile for a 
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period of 25 days. There were no further changes to the size-exclusion profile and soluble 
protein concentration after the 3rd day, remarkably, the size-exclusion profile on the 25th day 
indicated the protein was still monomeric: the observed peak retention volume was under 43 
kDa that comes matches up with the expected mass 32.5 kDa (23.9 kDa SgtB(68-269) 
E100Q + 1.6 kDa MmA + ~7.0 kDa CHAPS micelle) (Figure 4.13). We lost approximately 
25% of our original sample to precipitation, presumably because there is always some 
proportion of overexpressed SgtB protein that cannot bind MmA well because it is not 
optimally folded. Fortunately, the remaining 75% of the protein remained soluble, 
monodisperse and monomeric. We recovered this well-behaved protein that is thermally 
stable at room temperature by low g-force centrifugation to remove the precipitates. In 
summary, exposing the sample to ambient room temperature is an excellent way of removing 
heterogeneity in the protein sample: poorly behaved proteins are precipitated by this gentle 
“heat” treatment, leaving behind a pristine solution of monomeric and monodisperse MmA 
bound SgtB(68-269) E100Q. 
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Figure 4.12 Heat polishing the Moenomycin A bound SgtB(68-269) protein complex 
sample. (a) During Period 1, soluble protein concentration drops sharply from 600 µM to 480 
µM in the first 24 hours of exposure to ambient room temperature. The soluble protein 
concentration stabilizes at ~ 455 µM after 72 hours and remains at approximately the same 
level thereafter in period 2. (b) Moenomycin A bound SgtB(68-269) sample buffered at pH 
6.8 after 72 hours of exposure to ambient room temperature. (c) Moenomycin A bound 
SgtB(68-269) protein complex sample buffered at pH 7.5 after 72 hours of exposure to 
ambient room temperature. (d) and (e) Well-behaved Moenomycin A bound SgtB(68-269) 
protein complex sample buffered at pH 6.8 and 7.5 respectively.    
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Figure 4.13 Size-exclusion profiles of Moenomycin A bound SgtB(68-269) sample prepared 
using the methodology described in section 4.2.8. (a) Monomeric SgtB(68-269) protein stock 
prior to sample preparation, (b) Moenomycin A bound SgtB(68-269) sample at 550 µM after 
14 days exposure to ambient room temperature. (c) Moenomycin A bound SgtB(68-269) 
sample at 550 µM after 25 days exposure to ambient room temperature. 
 
4.2.8 Preparation of a stable, well-behaved MmA bound SgtB NMR sample at a final 
concentration of 550 µM. 
 
Thus far, our protein sample has been buffered with Tris base at a pH 7.5. Sample pH 
values greater than 7.5 can be problematic for NMR because spectral quality is impaired 
from the exchange of labile backbone and side chain amide protons with solvent protons. We 
lowered the pH of our sample by exchanging the basic Tris buffer to Sodium Phosphate 
buffer at a pH 6.8 while simultaneously introducing 5% (v/v) D2O required for deuterium 
field-frequency lock. This was accomplished using a PD-Minitrap G25 Sephadex cartridge 
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(GE Healthcare) that was pre-equilibrated in our final sample buffer containing 20 mM 
Sodium Phosphate at pH 6.8, 5% (v/v) D2O in addition to 500 mM NaCl and 8 mM CHAPS. 
 
Figure 4.14 Summary of the preparation methodology for a well-behaved Moenomycin A 
bound SgtB(68-269) at 550 µM. 
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A graphic summary of our sample preparation methodology is presented in Figure 
4.14. We prepared two 550 µM partially deuterated, 15N-labeled samples of MmA bound 
SgtB(68-269) E100Q, buffered at pH 6.8 and 7.5 for [1H,15N]-TROSY HSQC 
characterization. Briefly, His6-TEVpc-SgtB(68-269) E100Q was overexpressed and purified 
in D2O/15N-labeled M9 minimal media expression system developed in Chapter 3. 
Approximately 40 mg of His6-TEVpc-SgtB(68-269) E100Q was accumulated using this 
process, storing the monomeric fractions of the protein at ~20 µM (0.5 mg/mL) concentration 
to retard aggregation. The monomeric His6-TEVpc-SgtB(68-269) E100Q stock is then 
concentrated to 115 µM and digested with TEV protease. The digestion product, SgtB(68-
269) E100Q is then cleaned up by passage through a Ni-NTA IMAC column and 
immediately incubated with 1.3 equivalents of MmA at a final concentration of 40 µM for 3 
hours at 4 oC. The protein sample is then concentrated to 600 µM for buffer exchange. 
Finally, the sample is concentrated up to ~730 µM and incubated at 22 oC for 3 days. The 
precipitates are removed by low g-force centrifugation to obtain a highly concentrated well-
behaved, monomeric and monodisperse MmA bound SgtB(68-269) E100Q sample at 550 
µM. 
The [1H,15N]-TROSY HSQC spectra acquired on a 500MHz instrument equipped 
with a room temperature triple resonance probe was well-dispersed for both samples (Figure 
4.15 and 4.16). Not surprisingly, the spectrum acquired from the sample buffered at pH 6.8 
reveals additional amide proton peaks compared with the sample at pH 7.5 (Figure 4.17). 
Closer examination of the spectra revealed that 60-70% of the 286 expected peaks amide 
peaks are visible. Because Asparagine and Glutamine make up more than 17% of our 
SgtB(68-269) E100Q construct, the extensive overlap by their side chain amide protons alone 
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may account for half of these missing peaks (Figure 4.18). Additionally, SgtB contains a 
large number of alpha-helices which may result in extensive peak overlaps because the amide 
backbones sample a less diverse chemical environment.42 Peaks may be also be broadened in 
regions undergoing µs-ms conformational dynamics.43  
At this stage, we were ready to optimize the sample buffer by reducing the salt and 
detergent concentrations. A stable well behaved sample of Moenomycin A bound SgtB(68-
269) at 600 µM was prepared and exchanged into various buffers using PD-minitrap G25 
sephacryl column. Reducing the NaCl salt and CHAPS detergent concentrations resulted in 
the formation of soluble aggregates in 12 hours (Figure 4.19). This series of experiments 
show that the addition of Moenomycin A alone cannot prevent the formation of aggregates. 
The high salt and detergent levels were equally crucial in stabilizing the protein.    
 Currently, we are pursuing triple resonance experiments on a 800 MHz instrument 
equipped with a HCN salt-tolerant cryoprobe that will determine the feasibility of obtaining a 
full spectral assignment of our protein with a high-salt tolerant cryoprobe that also promises 
greater signal sensitivity. 
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Figure 4.15 [1H,15N]-TROSY HSQC of partially deuterated 15N-labeled Moenomycin A 
bound SgtB(68-269) sample at pH 6.8, prepared using the methodology described in Section 
4.2.8. 
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Figure 4.16 [1H,15N]-TROSY HSQC of partially deuterated 15N-labeled Moenomycin A 
bound SgtB(68-269) sample at pH 7.5, prepared using the methodology described in Section 
4.2.8.  
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Figure 4.17 Overlay of [1H,15N]-TROSY HSQC spectra of pH 6.8 versus pH 7.5 
Moenomycin A bound SgtB(68-269) samples. Indicated with red arrows are examples of 
additional peaks observed in the sample buffered at pH 6.8.  
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Figure 4.18 Accounting for the expected number of observed N-H peaks in the [1H,15N]-
TROSY HSQC spectrum of SgtB(68-269). (a) Expected number of N-H peaks in the 
spectrum. (b) Notably, 25% of the expected N-H peaks originate from glutamate and 
asparagines side chains N-H that tend to be crowded in a typical HSQC spectrum.  
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Figure 4.19 Optimizing the sample salt and detergent concentrations. (a) 600 µM sample of 
Moenomycin A bound SgtB(68-269) prepared using the methodology decribed in section 
4.2.8. (b) 600 µM sample of Moenomycin A bound SgtB(68-269) prepared using the 
methodology decribed in section 4.2.8. that has been exchanged into a buffer with a reduced 
salt concentration. (c) 600 µM sample of Moenomycin A bound SgtB(68-269) prepared 
using the methodology decribed in section 4.2.8. that has been exchanged into a buffer with a 
reduced salt concentration and no detergent. (d) 600 µM sample of Moenomycin A bound 
SgtB(68-269) prepared using the methodology decribed in section 4.2.8. that has been 
exchanged into a buffer with 500 mM NaCl and no detergent.   
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4.2.9 Insights into the structure of Moenomycin A bound SgtB 
In our quest to prepare a long-lived, monodisperse and monomeric sample of SgtB for 
protein NMR characterization, we have observed that ligand-free SgtB(68-269) has a strong 
tendency to aggregate at high concentrations even at temperatures as low as 4 oC. Studies 
have shown that proteins aggregate when natively folded monomeric proteins are able to 
sample a series of expanded conformations that are aggregation-competent. We believe that 
ligand-free SgtB(68-269) aggregates mainly because of conformational flexibility. 
Aggregation-prone surfaces are exposed in the due course of sampling many distinct 
conformations. The fact that monomeric MmA bound SgtB(68-269) does not form 
aggregates even after extensive exposure to ambient room temperature suggests that the 
aggregation-prone surfaces that exposed in the MmA bound SgtB(68-269) complex must be 
greatly reduced, and the large exposed hydrophobic surface on the base of the lower lobe 
does not have sufficient pliability to form moulded non-specific interaction interface with 
other protein partners. If this was not the case, then one should observe the aggregation and 
precipitation of the MmA bound SgtB(68-269) complex.  
 As a result, we believe that the ensemble of structures presented by MmA bound 
SgtB(68-269) must be structurally and dynamically distinct from its ligand-free form. 
Additionally, our [1H,15N]-TROSY HSQC data suggests that the MmA bound SgtB(68-269) 
complex retains some level of floppiness. Given that size-exclusion analysis of our protein 
sample suggests that the MmA bound SgtB(68-269) complex exists as a monomeric 
complex, we postulate that a number of missing amide backbone proton peaks in the 
spectrum may arise from flexible regions in the protein that are undergoing µs-ms 
conformational exchange that broadens out their signal. Because this SgtB construct was 
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identified by trimming disordered regions at the termini of the protein with a non-specific 
protease, Subtilisin A, we think that the majority of these pockets of flexibility originate from 
internal structures within the protein and not flexible termini. The lack of electron density in 
segments of the lower lobe region in the crystal structures of PGT domain from S. aureus 
PBP2, A. aeolicus PBP1A and E. coli PBP1B suggests this helix-loop region near the 
catalytic domain to be one obvious candidate. There may be other regions of flexibility that 
are critical for catalytic function/impairment of the enzyme that are not readily apparent from 
the crystal structures. A detailed comparison of the conformational dynamics between a 
MmA bound SgtB(68-269) complex with a Gal-Lipid IV bound SgtB(68-269) complex by 
NMR will shed light on this issue.  
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Chapter 4.3 Selected Materials and Methods 
S. aureus SgtB (D68-R269), overexpression plasmid was obtained from Dr. Alita Miller 
(Pfizer Global Research and Development, MTA:A12545). The pET30a plasmid containing 
6XHis-GB1A (pET30a:6XHis-GB1A) was obtained from Dr. Ricard Rodriguez-Mias, 
(Wagner group). Moenomycin A was prepared by Dr. Hirokazu Tsukamoto (Kahne group) 
and Yihui Wu (Kahne group). C15-(Z,E)-Farnesyl-MmA was synthesized by Dr. Hirokazu 
Tsukamoto (Kahne group). Protein biochemistry was performed by Yihui Wu (Kahne 
group). NMR spectra acquisition was performed by Dr. Ricard Rodriguez-Mias (Wagner 
group) and Dr. Haribabu Arthanari (Wagner group) on a Varian or Bruker spectrometer 
equipped with room temperature probe operating at 500 MHz field strength. Recycled D2O 
used for culture growth was purified and distilled by Dr. Tsyr-Yan Yu (Wagner group). TEV 
protease was prepared by Dr. Jiaoyang Jiang (Walker group). 
 
4.3.1 Cloning of His6-GB1A-SgtB(64-269) and His6-GB1A-SgtB(64-269)-gly GB1A 
 
sgtB gene containing SgtB(60-269) was PCR amplified from Staphylococcus aureus 
COL genomic DNA with KOD hotstart polymerase (Novagen) with BamHI and EcoRI 
restriction sites and subcloned into pET30a:6XHis-GB1A to give pET30a:6XHis-GB1A-
SgtB(60-269). sgtB gene containing SgtB(64-269) was PCR amplified from pET30a:6XHis-
GB1A-SgtB(60-269) using KOD hotstart polymerase (Novagen) with BamHI and EcoRI 
restriction sites subcloned into pET30a vector containing 6XHis-GB1A to give the 
expression vector pET30a:6XHis-GB1A-SgtB(64-269) for the protein His6-GB1A-SgtB(64-
269). 
 GB1A was PCR amplified from pET30a:6XHis-GB1A using the forward primer 5’-
AAA-AAG-AAT-TCA-TGC-AGT-ACA-AAC-TGA-TCC-TGA-ACG-G-3’ and reverse 
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primer 5’-AAA-AAC-TCG-AGT-TAT-TCG-GTA-ACG-GTG-AAG-GTT-TTG-3’, 
incorporating EcoRI and XhoI restriction sites and inserted into pET30a:6XHis-GB1A-
SgtB(64-269) to give pET30a:6XHis-GB1A-SgtB(64-269)-GB1A. C-terminal GB1A glycine 
linker vector pET30a:6XHis-GB1A-SgtB(64-269)-gly-GB1A was made using site-directed 
mutagenesis kit Quikchange II (Agilent/Stratagene), in the presence of 5% DMSO (v/v) 
(Sigma Aldrich), with the following modified PCR program: (1) 95 oC – 2 min, (2) 95 oC – 1 
min, (3) 55 oC – 1 min, (4) 68 oC – 10 min, (5) 68 oC – 7 min, and (6) 4 oC, looping steps (2) 
to (4) 18 times over. The forward primer used to create this insertion is 5’-TCA-ACA-GGC-
TAT-GTC-ACA-ATT-AAA-TCG-TGG-AGA-ATT-CAT-GCA-GTA-CAA-ACT-G-3’ and 
the reverse primer is 5’-CAG-TTT-GTA-CTG-CAT-GAA-TTC-TCC-ACG-ATT-TAA-
TTG-TGA-CAT-AGC-CTG-TTG-A-3’ that were designed using Agilent/Strategene’s 
proprietary primer design software available online at http://www.genomics.agilent.com. The 
integrity of both vectors pET30a:6XHis-GB1A-SgtB(64-269) and pET30a:6XHis-GB1A-
SgtB(64-269)-gly-GB1A were confirmed by DNA sequencing. 
 
4.3.2 Detailed preparation of Moenomycin A bound SgtB(68-269) NMR sample 
M9 minimal media for overexpressing partially deuterated 15N-labeled His6-TEVpc-
SgtB(68-269) was prepared using the formulation presented in Chapter 3, incorporating 1.2 g 
of 15NH4Cl (Cambridge Isotopes) in place of unlabeled ammonium chloride, and recycled 
D2O (originally purchased from Cambridge Isotopes) in place of H2O. His6-TEVpc-SgtB(68-
269) is overexpressed and purified as described in Chapter 3. Only the most concentrated 
fractions (~ 20 µM, 0.5 mg/mL) coming off the FPLC near the maximum 280nm absorbance 
are pooled. A total of ~40 mg of partially deuterated, 15N-labeled His6-TEVpc-SgtB(68-269) 
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is stockpiled from 4 successive rounds of preparation. The entire stockpile of partially 
deuterated, 15N-labeled His6-TEVpc-SgtB(68-269) is concentrated using an angled rotor 
benchtop centrifuge (Eppendorf) to 115 µM using 1% BSA (w/v) passivated Amicon Ultra 
concentrators (10K MWCO) at 4 oC, 1500Xg. TEV protease at 0.5 mg/mL is added to the 
protein stock and the digestion reaction is incubated at 4 oC for 24 hours to yield SgtB(68-
269). SgtB(68-269) is purified by repeated passage (3X) through Ni-NTA affinity column 
which is then washed with 1 column volume of buffer (20 mM Tris pH 7.5, 500 mM NaCl, 8 
mM CHAPS) to give a protein stock at ~ 60-80 µM. The protein is immediately added to a 
buffer containing 1.3 equivalents of Moenomycin A, 1.3 equivalents of MgCl2, 20 mM Tris 
pH 7.5, 500 mM NaCl, and 8 mM CHAPS at 4 oC for 3 hours, giving a final protein 
concentration of 40 µM. Moenomycin A bound SgtB(68-269) complex is concentrated to 
600 µM using 1% BSA (w/v) passivated Amicon Ultra concentrators (10K MWCO) at 4 oC, 
1500Xg. 
A Sephacryl PD-minitrap G25 (GE Healthcare) column prepared for buffer exchange by 
washing with 3 column volumes of H2O, followed by 6 column volumes of Buffer A 
containing 5% D2O (v/v), 20 mM sodium phosphate pH 6.8, 500 mM NaCl, and 8 mM 
CHAPS at room temperature. The Moenomycin A bound SgtB(68-269) complex is loaded 
onto the Sephacryl PD-minitrap G25 column at room temperature, and eluted with Buffer A 
per the manufacturer’s instructions to yield a final protein complex concentration of ~ 300 
µM. Moenomycin A bound SgtB(68-269) is concentrated with 1% BSA (w/v) passivated 
Amicon Ultra concentrators (10K MWCO) at 4 oC, 1500Xg to the target concentration e.g. 
600 µM and incubated at ambient room temperature (22 oC) for 3 days. The precipitated 
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protein in the sample is removed by centrifugation at 1500Xg for 30 min at 4 oC, soluble 
fraction is retained as the protein sample for NMR spectroscopy. 
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Chapter Five: Prospective studies on SgtB 
 
 
 
 
 
 
 
 
 
 
The work presented in this chapter is a result of a collaboration between the Kahne, Walker 
and Wagner research groups at Harvard Medical School. The data acquisition for the 
[15N,1H]-TRACT experiment mentioned in the text was performed by Dr. Tsyr-Yan Yu 
(Wagner).  
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5.1. Opportunities with a Lipid IV bound SgtB sample. 
The observation of SgtB transglycosylation rate-enhancement by Gal-Lipid IV 
prompted us to pursue an NMR structure-based strategy that can give insight into the 
conformational dynamics that accompany the initiation of glycan synthesis. Ideally, this can 
be accomplished if we can produce an NMR-amenable ligand-free SgtB sample. Based on 
our results in Chapter 4, we believe that it will be difficult to obtain monodisperse and 
monomeric ligand-free SgtB at concentrations amenable for structural characterization, either 
by X-ray crystallography or NMR because the protein aggregates at high concentrations 
required for structural characterization. The hydrophobic amino acids on the exposed surface 
of SgtB can be mutated to more polar variants to minimize non-specific adhesion between 
proteins - even then, it may prevent protein aggregation.1 The conformational flexibility of 
the protein might reveal internal sites that can promote non-specific association. 
On the upside, it may be possible to obtain a stable, well-behaved sample of Lipid IV 
bound SgtB(68-269) E100Q complex in the near future for X-ray crystallography or solution 
structure by NMR using the sample preparation methodology presented in section 4.2.8 of 
this thesis. We have established that SgtB(68-269) E100Q can be stabilized for NMR 
solution structural studies by Moenomycin A (MmA), possibly by locking it in a 
conformational state that minimizes the exposure of aggregation-prone surfaces and 
preventing the protein from sampling aggregation-competent conformations. Because Lipid 
IV is able to induce conformational changes in SgtB such that it takes on a distinct 
"activated" rate-enhanced state, we believe that Lipid IV will most likely be able to provide a 
similar stabilizing effect to SgtB. Although the affinity of Lipid IV for SgtB has never been 
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directly measured, studies have shown that it because SgtB has to bind Lipid IV tightly in 
order to synthesize a long glycan strand in a processive fashion.2 
In order to test this possibility, milligram quantities of Gal-Lipid IV will be required. 
As mentioned in Chapter 4, it is a non-trivial task to obtain Gal-Lipid IV in such quantities.3,4 
An improved synthesis of Lipid IV which is more robust and scalable is being developed 
within our research group. Efforts to scale up the synthesis are ongoing. The structural 
characterization of the Lipid IV bound SgtB complex will provide insight into the 
"activated"-state of the enzyme. Specifically, the SgtB:Lipid IV complex sample presents a 
unique opportunity to study the conformational dynamics that accompany downstream events 
stemming from the uptake of Lipid II in the acceptor site such as the translocation of newly 
synthesized glycan strand from the acceptor site to the donor site. For instance, the uptake of 
Lipid II by SgtB may trigger off conformational rearrangements that remodel the active site 
for translocation by unfolding of the alpha-helix that physically separates the donor and 
acceptor site.5 By comparing the change in conformational dynamics before and after the 
incorporation of Lipid II, and mapping these “hotspots” of activity to the structure of the 
Lipid IV bound SgtB complex, one can uncover key amino acid residues that enable the 
physical communication and coordination between different moving parts in the protein. 
Extending our analysis to the conformational dynamics of MmA bound SgtB complex may 
reveal entropy related subtleties that make MmA potent inhibitor of the PGTs. 
 
5.2. Path towards Lipid IV bound and MmA bound SgtB solution structures. 
In Chapter 4, we have established a preparation method that yields a SgtB sample that 
is sufficiently long-lived and well-behaved for the collection of higher-order triple resonance 
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correlational data sets required for the assignment of the individual H, C, and N atom 
resonances. Subsequently, throughspace conformational restraints can be measured via 
NOESY-based experiments. Additionally, atomic and bond torsional restraints are collected 
by residual dipolar coupling experiments. However, the road towards a solution structure of 
SgtB is far from paved.6 
  While the computation of an ensemble of solution structures from geometrical 
restraints has become routine in the recent years with the advent of powerful computational 
software, the task of peak identification and assignment is still largely a manual, time 
consuming art in itself.7 Theoretically, the redundent, overlapping nature of triple resonance 
correlational data sets enable a spectroscopist to assign peaks by moving sequentially from 
the N to C terminus along the protein polypeptide chain.8 However, unresolved and missing 
peaks often derail such efforts. We expect the peak assignment exercise for the MmA bound 
SgtB complex to be challenging because our [1H,15N]-TROSY HSQC spectrum only displays 
approximately 60-70% expected peaks. This is not surprising because SgtB, as seen from its 
crystal structure, comprises of 10 alpha-helices which translates into a high degree of peak 
overlap due to inherently narrower chemical shift dispersion of alpha-helical structures.9  
There are no easy tricks to increase peak count of a sample. The most direct way is to 
improve the signal intensity by increasing protein concentration of the NMR sample. We 
prepared a 1 mM sample of partially deuterated 15N-labeled MmA bound SgtB(68-269) 
E100Q and we observed that the peaks from the HSQC fingerprint were qualitatively broader 
than that of a 550 µM sample. [15N,1H]-TRACT experiments (with Dr. Tsyr-Yan Yu) suggest 
a molecular weight of approximately 60 kD, suggesting dimerization at high protein 
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concentrations (>550 µM).10 More investigations will have to be done in terms of finding the 
optimal concentration for making sophisticated NMR measurements. 
  Increasing the level of deuteration of our sample can also minimize signal losses due 
to spin relaxation.11 Additionally, this will also enable one to take full advantage of the 
TROSY effect. This is especially crucial for triple resonance NMR experiments which have 
many coherence transfer steps.12 Ultimately, the most efficacious way to obtain a complete 
assignment of the protein may be to isotopically label a select number of amino acids in a 
combinatorial fashion in order to identify a greater number of amino acids resonances on the 
HSQC spectra that can be used as anchor points for sequential assignment.13 Successful 
implementation of this assignment strategy will hinge on our ability to develop a cell-free 
expression system that will allow the efficient incorporation of select isotopically labeled 
amino acids into SgtB.14 
 
5.3. Prospective for a High-Throughput Screen for New Inhibitors of PGTs 
The synthesis of peptidoglycan is necessary for bacterial growth and survival.15 The 
PGTs are the only known, highly conserved enzymes that can assemble the polysaccharide 
backbone of peptidoglycan, hence they are a validated target for development of new 
antibacterials.16 The Moenomycin family of antibiotics are the only known class of 
molecules that inhibit the transglycosylase function of the PGTs.17 In particular, 
Moenomycin A has potent antibacterial activity against Gram-positive pathogens. 
Unfortunately, its clinical development has been hampered by its non-specific interaction 
with serum albumin, resulting in an unfavorable pharmacokinetic profile (a long half-life and 
low oral bioavailability) for the molecule. Various attempts to remove or shorten the 
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offending appendages on Moenomycin A such as its C25-lipid moiety resulted in a dramatic 
decrease in its potency.18,19 Attempts to reduce the size of the molecule in order to improve 
its potency against Gram-negative pathogens have been unsuccessful thus far.20 The 
challenges encountered in optimizing the complex pharmacophore of Moenomycin A create 
an impetus to discover new chemical structures that inhibit the PGTs in the same manner as 
Moenomycin A.21 
In principle, new inhibitors of PGT transglycolase activity can be identified by a 
high-throughput screen that employs a fluorescent-polarization probe displacement format 
(Figure 5.1). Such screens are relatively easy to scale and implement because they are 
formatted for a simple mix-and-measure protocol that does not require additional 
downstream processing of the microplate well contents.22 Because Moenomycin A is a 
known inhibitor of the PGTs, one can design a fluorescent-polarization probe by attaching of 
a fluorescent moiety as an appendage to Moenomycin A. Such a probe would enable the 
screen to identify compounds that bind to the PGTs at the same site as Moenomycin A. 
 
 
Figure 5.1 High throughput screen for PGT inhibitors using a fluorescent polarization probe 
displacement format. 
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In practice, it is difficult to implement a high-throughput screen of the aforesaid 
format because of several factors: (1) Enzyme-based high-throughput screens require large 
multimilligram (>20 mg) quantities of protein material at high levels of purity so that assay 
readouts can be directly attributed to the enzyme target of interest. As mentioned in earlier 
chapters, it is hard to obtain large quantities of pure, well-behaved PGT enzyme. Previous 
attempts at developing high-throughput screens for transglycosylase inhibitors circumvented 
this problem by using crude bacterial cell-membrane extracts as a source for PGT enzymes.23 
The use of impure sources of enzyme requires the use of a probe that binds specifically to the 
target enzyme of interest. It is not known whether Moenomycin A is able to form some level 
of interaction with other enzymes that are present in the bacterial cell-membrane extract. This 
may result in the accumulation of off-target hits, increase the burden of hit validation and 
thus decrease the efficiency of the screen. (2) The synthetic chemistry used to manipulate and 
modify the Moenomycins is complex.24 Although the first total synthesis of Moenomycin A 
has been reported in 2006, the development of chemically-modified probes has been slow to 
come forth. The challenges encountered in handling lipid-glycerate moieties that are prone to 
acid-catalyzed rearrangements and oxidation processes as well as the difficulties in 
glycosylating a lipid-glycerate moiety hamper the range and physical quantity of probes that 
can be produced for tuning the binding affinity towards the PGTs – a crucial parameter in a 
competitive displacement screen.25,26,27 
The work in this thesis has enabled the rapid preparation of large quantities of 
monodisperse and monomeric SgtB – 7 mg from 1 liter of Luria-Bertani media. Assuming 
that 0.1 µg of SgtB is required per compound well, one week of preparative purification of 
SgtB can accumulate 100 mg of SgtB that can enable a screen against 1 million compound 
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library. Moreover, using SgtB as a screening target carries the benefit that the hits identified 
will bind to SgtB, PGT from the clinically relevant pathogen S. aureus that may play a 
critical role in salvaging peptidoglycan biosynthesis under stressful conditions.28 As more 
robust methods for synthesizing fragments of Moenomycin A come online, we are confident 
that a well-tuned fluorescent probe can be designed and synthesized, finally enabling us to 
carry out a well-defined high-throughput screen for transglycosylase inhibitors. 
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